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ABSTRACT
ASSESSING BASELINE AND POST-DISCHARGE RISK FACTORS IN SUBJECTS WITH
AND WITHOUT SLEEP APNEA UNDERGOING ENDOSCOPY WITH DEEP SEDATION
Background: Outpatient procedures encompass over 60% of all surgeries in the United States,
and the prevalence of obstructive sleep apnea (OSA) remains high among adult surgical
ambulatory patients. Ambulatory surgery poses problems for patients with OSA because
narcotics and anesthetics used during surgery can complicate the negative effects of OSA,
leading to cardiac events, brain hypoxia, and even death. This study was designed to evaluate the
prevalence of cardiopulmonary risk factors among post endoscopic patients with diagnosed and
undiagnosed sleep apnea. Methods: The study involved a prospective, descriptive cross-sectional
design and incorporated a pre-test or post-test data collection approach, using Actigraphy, pulse
oximetry and 24-hour ECG monitoring via Bluetooth technology to monitor outpatients
undergoing endoscopy with deep Propofol sedation. Patients were recruited pre-procedure to
obtain a resting baseline ECG, and pre-procedure values were then monitored post procedure
continuously for 24 hours. A p-value less than 0.05 was considered to be statistically significant.
A target sample included 50 adult outpatients from a Florida suburban endoscopy center.
Results: Pulse oximetry and Actigraph scores revealed no difference based on OSA. The
ANOVA for oxygen desaturation events and sleep quality indices reflected no differences across
groups. Sleep quality had no measurable influence on adverse events and was similar across
groups; participants diagnosed with OSA slept longer than those in the untreated or no OSA
group. Regressions for sleep quality indices reflected no differences among groups. Conclusions:
There remains a lack of literature on cardiopulmonary and ECG indicators of cardiac risks in
patients with OSA in the 24 hours following discharge from ambulatory surgery. This
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dissertation characterized the ECG at baseline and post-discharge among post-endoscopy
outpatients with OSA and without OSA. Further research is recommended.

Chapter 1: The Problem

Introduction
Background of the Problem
Sleep disordered breathing refers to the entire spectrum of sleep-related breathing
abnormalities including upper airway resistance syndrome with and without snoring, central
sleep apnea, and obstructive sleep apnea (OSA; Garcha, Aboussouan, & Minai, 2013). OSA is a
sleep disorder that involves intermittent or complete obstruction of the airway during sleep
(Garcha et al., 2013). OSA is associated with several negative consequences including
cardiovascular disorders, neurocognitive dysfunctions, and metabolic dysfunction, and exists in
an estimated 3 to 7.5% of the population of the United States (Mador, 2013). The prevalence of
OSA is increasing in the general population and remains high among adult surgical patients,
including patients of ambulatory surgery (Joshi, Ankichetty, Gan, & Chun, 2012; Mador, 2013;
Singh, Liao, & Kobah, 2013). Benumof (2016) urged anesthetists to effect immediate change by
addressing OSA in surgical patients because of the high risk of adverse outcomes and death. The
current study represents an answer to that call and was designed to examine the clinical and ECG
risk factors of cardiac risks in OSA patients in the 24 hours immediately following discharge
from ambulatory surgery.
Ambulatory surgery refers to any surgical procedure that allows the patient to go home
the same day (Hall, Schwartzman, Zhang, & Liu, 2017). The number of ambulatory surgeries
1

performed nationwide in hospital outpatient departments or freestanding ambulatory centers has
grown exponentially from 3.7 million to over 48 million in the period spanning 1981 to 2010
(Hall et al., 2017). Outpatient procedures encompassed over 60% of all surgeries in the United
States in 2011, as compared to 19% in 1981(American Hospital Association, 2014).
Ambulatory surgery can pose serious problems for patients with OSA because sedatives
and anesthesia used during surgery may complicate and compound the negative effects of OSA,
leading to cardiac events, brain hypoxia, and even death (Joshi et al., 2012; Mador, 2013). The
possibility of these adverse events poses unique risks to ambulatory surgery patients because
post-operative patients are released into settings lacking skilled nursing care (Kent, Metzner, &
Bollag, 2014). Although studies focused on post-operative recovery of outpatients with OSA in
hospital settings are beginning to emerge, few researchers have monitored and studied the postoperative recovery of outpatients with OSA in patients’ homes (cf. Biddle et al., 2016). There is
still scarce information on the negative consequences for ambulatory surgery patients at home in
the immediate post-operative period and particularly for those patients with undiagnosed
moderate to severe OSA.
Statement of the Problem
There are an increasing number of ambulatory surgeries, such as endoscopic procedures,
as well as an increasing number of patients with OSA undergoing surgery in ambulatory settings
(Hall et al., 2017; Joshi et al., 2012). Information on the negative consequences for ambulatory
surgery patients and particularly those with OSA shortly after being discharged from ambulatory
surgery was scarce. It is important that patients who have diabetes, hypertension, coronary artery
disease, or pulmonary disease be adequately assessed and prepared based on the needs of their
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conditions before surgery. The current study helped identify whether selected patients with OSA
risk factors require special care prior to and after their procedures.
Purpose of the Study
The purpose of this study was to assess the prevalence of patient risk factors for
cardiopulmonary adverse events in a diverse range of patients presenting for outpatient
endoscopy under deep propofol sedation, and to determine the relative risk of adverse
cardiopulmonary events occurring in the first 24-hours post-procedure following deep propofol
sedation for endoscopy in patients with or without OSA. The proposed study was designed to
evaluate the prevalence of cardiopulmonary risk factors among post endoscopic patients with
diagnosed and undiagnosed sleep apnea. In doing so, the study made a meaningful contribution
to the literature regarding the outcomes and management of patients with undiagnosed and
untreated OSA in the Ambulatory Surgery Center (ASC) environment. It further helped to define
the associated risks and inform decisions outlining care for ASC patients. For instance,
diagnosing sleep apnea and prescribing continuous positive airway pressure (CPAP) therapy,
prior to surgery, significantly reduced postoperative cardiovascular complications, specifically
cardiac arrest and shock, by more than half (Mutter, Chateau, & Moffatt, 2014). This study
provided additional data for future projects on ensuring preoperative preparedness and
postoperative monitoring, while triggering identification and risk amelioration in this burgeoning
population of patients.
Rationale and Theoretical Framework
According to the Centers for Disease Control and Prevention, the rate of sleep disorders
has reached epidemic proportions, affecting 1 in 3 American adults (Liu et al., 2014). Sleep
disorders and OSA are associated with adverse events ranging from loss of productivity to
3

increased risk of cardiopulmonary illness and related death (Gami et al., 2013). The National
Center on Sleep Disorders Research, a subsidiary of the National Heart, Lung, and Blood
Institute within the National Institutes of Health, was established in 1993 to address this serious
public health concern. The most current NIH Sleep Disorders Research Plan was released in
2011, with the overall goal of better understanding sleep disorders and circadian biology to
develop therapies that will make a significant impact on this serious public health epidemic
(National Center on Sleep Disorders Research, 2011). With OSA in epidemic proportions,
greater research is needed on OSA among ambulatory surgery patients released from clinical
settings within 24-hours post-procedure.
Almost two decades since the U.S. Institute of Medicine report, To Err Is Human (1999),
most errors in patient care are still caused by faulty systems, processes, and conditions that lead
people to make mistakes or fail to prevent them. As many as 25% of patients undergoing surgery
have OSA, but few hospitals or ASCs have policies that address the risks of this condition during
the perioperative period, and fewer follow recommended consensus statements (Joshi et al.,
2012). How patients with OSA are identified, determined suitable for ambulatory surgery, and
discharged after ambulatory surgery represents a trajectory of problems inherent within the
system that can lead to potential patient harm (Joshi et al., 2012). Not considering the needs of
patients with OSA in ASC settings and the possible associated cardiac sequelae represents a
latent risk factor that can be mitigated by information generated by this study.
Reason (2000) studied error management in clinical settings and developed the Swiss
Cheese Model (SCM) that holds that most errors or accidents are caused not so much by
inevitable human mistakes, but rather by an organization’s incomplete layers of error protection
that allow errors to pass through unchecked on their way to causing harm. These layers of
4

protection are like slices of Swiss cheese with gaps that may allow errors to pass through
unchecked on their way to causing harm. Holes in the SCM represent gaps in organizational
defenses. However, unlike holes in real Swiss cheese, these holes are dynamic. They open, close,
and change location over time. Holes in these layers of protection happen for two reasons: active
failures and latent conditions (Reason, 2000).
Active failures involve problematic acts committed by those in direct contact with
patients or the system, and they take several forms (e.g., lapses, slips, mistakes, and procedural
violations; Reason, 2000). Latent conditions refer to inevitable problems inherent within the
system that arise from the decisions of procedure architects, upper level management, and
designers (Reason, 2000). Holes in any one layer of protection may lead to errors that usually do
not result in negative outcomes. Latent conditions may allow holes to align to permit a trajectory
of accident opportunity, potentially bringing hazard or harm to the patient or system. The
trajectory path will show that errors result from holes in multiple layers of safeguards (Reason,
2000).
This study is innovative because, to date, no researchers have reported both the clinical
(e.g., actigraphy, pulse oximetry, anthropometric parameters, etc.) and electrocardiographic
(ECG) indicators of cardiac risks that occur in this group of patients, particularly in the 24 hours
immediately following discharge from ambulatory surgery (Rotenberg, 2013). Amidst this dearth
of scientific evidence, organizations concerned with patient safety, such as the American Society
of Anesthesiologists, have recommended that patients with OSA be observed for extended
periods of time and routinely receive CPAP (Joshi et al., 2012). Lack of clinical and ECG
indicators of cardiac risks in patients with OSA in the 24 hours immediately following discharge
from ambulatory surgery may represent a gap in healthcare that may lead to adverse patient
5

outcomes. An innovative approach is necessary to report the clinical and ECG risk factors of
cardiac risks that occur in OSA patients in the 24 hours immediately following discharge from
ambulatory surgery.
Some institutions require that certain populations of patients with OSA who have
received particular narcotics be held overnight and not undergo surgery in ASCs (Rotenberg,
2013). Healthcare providers are rightfully concerned about the increased risk of adverse events
for OSA patients. Holding patients overnight may prove to be unnecessary and is inconsistently
practiced (Memtsoudis & Stundner, 2014). The current study was designed to examine the
clinical and ECG risk factors of cardiac risks in OSA patients in the 24 hours immediately
following discharge from ambulatory surgery.
Design and Methods
Within this study, the researcher assessed the relationship between cardiac risk factors
and OSA 24 hours before and after sedation. Data was collected before and after the treatment
was administered. The study utilized a pre/post-procedure, prospective, descriptive crosssectional design. The primary goal of this study was to assess the baseline and post-discharge
clinical and ECG risk factors of cardiac risk among post-endoscopy outpatients during the 24
hours before and following discharge from the ASC. The participants received deep Propofol
sedation during their procedure. This study aimed to determine whether participants with
undiagnosed or untreated OSA have a higher risk of potentially fatal cardiac or respiratory events
compared to patients using appropriate treatment for OSA (i.e., dental appliance, CPAP, and
patients who do not have OSA.
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Research Questions
The following research questions guide the study: RQ1: What is the prevalence of known
ECG characteristics for cardiac events among pre-endoscopic patients with high and normal
STOP-bang scores on resting 12-lead ECGs clinical (pulse oximetry and actigraph derived sleep
quality scores) and ECG characteristics of cardiopulmonary risk in post-endoscopy outpatients
with undiagnosed or untreated OSA, post-endoscopy outpatients receiving treatment for OSA,
and post-endoscopy patients without OSA?
The variables included in the study for Research Question 1 were clinical (pulse oximetry
and actigraph derived sleep quality scores) and ECG risk factors of cardiac risk. The researcher
conducted descriptive statistics to address Research Question 1. Descriptive statistics were used
to represent the prevalence of clinical (pulse oximetry and actigraph derived sleep quality
scores), ECG risk factors and participant group: post-endoscopy outpatients with undiagnosed or
untreated OSA, post-endoscopy outpatients receiving treatment for OSA, and post-endoscopy
patients without OSA.
RQ2: Among post-endoscopic patients receiving propofol, using a rhythm event recorder
(BodyGuardian Heart) are there statistically significant differences in the frequency of oxygen
desaturation events and tachy-brady-arrhythmias over 24 hours between outpatients with
undiagnosed or untreated OSA, and post-endoscopy patients with and without a medical
diagnosis of OSA?
The researcher conducted analyses of variance (ANOVA) tests for Research Question 2.
For Research Question 2, the dependent variables are ECG and pulse oximetry. These dependent
variables were compared among three groups of participants: post-endoscopy outpatients with
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undiagnosed or untreated OSA, post-endoscopy outpatients with a medical diagnosis of OSA
who are using CPAP, and post-endoscopy patients without OSA.
RQ3: Among pre-endoscopic patients receiving propofol, using a resting 12-lead ECG,
are there statistically significant differences in the duration of resting heart rate, QRS duration,
QTC duration and ST segment deviation between outpatients with undiagnosed or untreated
OSA, and post-endoscopy patients with and without a medical diagnosis of OSA?
For Research Questions 3, the researcher conducted binary logistic regression to assess
the amount of explained variance between sleep efficiency and cardiac adverse outcomes.
Cardiac adverse outcomes were defined as the presence of bradycardia and tachycardia. The
variables of interest for Research Question 3 are sleep quality and number of adverse events.
RQ4: Does sleep quality influence pulse oximetry readings? The variables of interest for
Research Question 4 are sleep quality and pulse oximetry readings this relationship was assessed
using regression analyses.
Clinical factors were operationalized as observations related to anthropomorphic
measurements, oximetry results, and sleep during the data collection process. Cardiopulmonary
risk factors comprised the 11 outcomes related to healthy cardiac function. An adverse event was
defined as any negative medical occurrence following the use of Propofol sedation, regardless of
its explicit connection to Propofol. Examples of adverse events would be decreased respiratory
effort that resulted in sustained oxygen desaturations below 90% on room air or aggravation of
or new onset arrhythmias. If the adverse event was deemed acutely detrimental, the participant
was instructed to follow-up with their primary care physician. If the adverse event was not
considered detrimental, no follow up steps were recommended. Sleep quality was
operationalized as the sleep efficiency score from actigraphy.
8

The findings from the first research question addressed the dearth of literature related to
the prevalence of clinical and ECG risk factors of cardiac risk in this burgeoning population of
patients. Findings from the second research question provided information related to whether
outpatients with undiagnosed OSA who receive sedation are subject to increased cardiac risk as
determined by the presence of tachy-brady arrhythmias obtained from cardiac monitoring. The
remaining questions regarding sleep quality were addressed by data retrieved from the actigraph
watch and analyzed with the accompanying Action4 software package. Table 1 lists
cardiopulmonary risk factors comprised the 11 outcomes related to healthy cardiac function.

9

Table 1: Cardiopulmonary Risk Factors
Variable

HR
QRS
duration
QTc
Interval
LVH

LBBB
fQRS

ST event

PVC

NSVT

Hypoxia

Definition

Variable Type

Mean R-R interval of all QRS
complexes during the duration of
the recording
Mean QRS onset to offset duration
of all leads on the standard 10-s
ECG
Mean QRS onset to T offset
interval of all leads on the
standard 10-s ECG corrected for
HR using Bazett formula
The presence of this pattern on the
standard 10-s ECG using Cornell
voltage criteria

Continuous

The presence of this pattern on the
standard 10-s ECG using AHA
criteria
RSR morphology > 2 R’ or
notching in the nadir of S wave
with a narrow QRS (<120ms) or >
2 R’ or notching in the nadir of S
wave with a widened QRS
The presence of at least 1 episode
of ST depression of >0.5 mm in
leads V2-V3 or > 1 mm in all
other leads in > or = 2 contiguous
leads for at least 5 min at any time
The presence of frequent
premature ventricular contractions
at rate of > or = 10 per hour for
the duration of Holter recording.
At least 1 episode of > or = 3
consecutive ventricular beats at a
rate of > 120 beats per minute

Dichotomous

Pulse oximeter reading < or
= 90 percent
OSA
The intermittent cessation of
Sleep
breathing
Efficiency Ratio of total time spent
asleep in a night compared
to total time spent in bed.

Continuous
Continuous

Continuous

Cutoff for
Cardiac Events
> 75 beats per
minute
(Jouven et al.)
>120 ms
(Goldberger et
al.)
> 470 ms
(women) or
>450 ms (men)
(Straus et al.)
>20 mm
(women) or > 23
mm (Priori et
al.)
Present
(Surawicz et al.)

Clinical Significance
Poor sympathetic tone
Abnormal
conduction/myocardial
damage
Abnormal global
repolarization
Myocardial strain

Abnormal
conduction/myocardial
damage
Myocardial scarring

Dichotomous

Present
(Das et al.)

Dichotomous

Present
(Holmvang et
al.)

Transient myocardial
ischemia

Dichotomous

Present
(Goldberger et
al.)

Vulnerability to fatal
arrhythmia

Dichotomous

Present
(Goldberger et
al.)

Vulnerability to fatal
arrhythmia

Dichotomous Present
(Cintra et al.)
Continuous STOP-BANG
>3
Continuous
> 85%

Vulnerability to fatal
arrhythmia
Vulnerability to
arrhythmia
Vulnerability to
arrhythmia

Note. Abbreviations: fQRS, fragmented QRS complex; HRV, HR variability; LBBB, Left bundle branch block;
LVH, left ventricular hypertrophy; PVC, premature ventricular contraction; QTc, corrected QT interval, OSA;
obstructive sleep apnea.

10

Importance of the Study
Despite the numerous advancements in our understanding of the pathogenesis and
clinical consequences of this disorder, a majority of those affected remain undiagnosed (Peppard,
Young, & Barnet, 2013). The continued prevalence of OSA combined with obesity trends and
hypertension puts the population at serious risk of mortality and morbidity. The lack of
information on the clinical and ECG risk factors of cardiac risks that occur in OSA patients
within the 24 hours immediately following discharge from ambulatory surgery may represent a
structural shortcoming in healthcare leading to adverse patient outcomes (Reason, 2000).
As is reflective of the dearth in epidemiological sleep studies, recent evaluations of the
risks associated with undiagnosed moderate to severe OSA in surgical populations needs to be
determined, but previous estimates show that OSA is more prevalent among surgical patients
than in the general population (Singh et al., 2013). Further, there is a higher rate of perioperative
complications in those with OSA compared to those without OSA (Peppard et al., 2013). ASCs
offer patients the convenience of having surgical procedures performed outside of main hospital
settings. The increased demand for these services, and the fact that over 10 million
gastrointestinal (GI) endoscopic procedures are performed each year in the United States,
suggests that hospitals and health care facilities must proactively manage the safety and
economic implications of OSA patients (Joseph et al., 2016).
Adverse in-hospital events for all ASC patients are less than 1%, with major morbidity
occurring with a frequency of approximately 0.1% (Kent et al., 2014). There is a void in the
literature regarding the consequences for OSA patients in the first 24 hours at home after
discharge from the ASC. The long-term adverse effects of OSA on health outcomes are well
documented, while effects in the perioperative arena have only recently been systematically
11

assessed (Kaw, Pasupuleti, Walker, Ramaswamy, & Foldvary-Schafer, 2012; Mutter, Chateau, &
Moffatt, 2014; Peppard et al., 2013). To date there are no published studies that have included
systematic, in-home cardiopulmonary monitoring (e.g., Actigraphy, electrocardiogram, pulse
oximetry) of patients after discharge from ASCs.
The present study involves an innovative approach, and patients were monitored for 24
hours in their homes before their procedure and following ASC discharge. The Cardiac monitor
was worn optimally overnight post procedure for up to 24 hours, as it is clinically important to
evaluate at least 24 hours of cardiac monitor data because there is greater risk for adverse events
in the first 24 hours (Zimetbaum & Goldman, 2010). The prevalence of OSA among candidates
for elective endoscopies and colonoscopies is estimated to be greater than 40% largely due to the
high rate of coexisting diseases such as obesity, hypertension, pulmonary disorders, and diabetes,
as well as a high number of patients over the age of 50 years (Boese, Ransom, Roadfuss, Todd,
& McGuire, 2014).
Assumptions
The main assumption of this study was that ambulatory surgery patients, particularly
those with undiagnosed sleep apnea, are especially vulnerable to cardiopulmonary peril once
released from the immediate postoperative period in the post-anesthesia care unit (PACU) to
their homes.
Limitations
This convenience sample itself was a limitation because it was not as representative as a
random sample. Even though this study was limited to a convenience sample of endoscopy
patients, it may still be representative of ambulatory surgery outpatients since endoscopy patients
represent the largest proportion of ambulatory surgeries. Because of requirements and procedures
12

specific to other types of ambulatory procedures, results may not generalize well to patients
undergoing ambulatory surgeries other than endoscopies. Additionally, another limitation to
generalizability is that propofol is not standard for all ambulatory procedures, and the effects of
other anesthesia on OSA patient’s post-procedure may differ from those of propofol.
Scope and Delimitations
This study was designed to measure the relationship between cardiac risk and OSA 24
hours pre- and 24 hours post-sedation, with data being collected before and after the treatment is
administered, using a pre/post-test, cross-sectional design. This study focused on the description
of cardiopulmonary risks that may be encountered in ambulatory endoscopy patients, as
monitored by pulse oximetry, cardiac monitor and actigraph. While some findings may be useful
in the care of other categories of ambulatory patients, this study was not designed to examine the
cardiopulmonary risks that may be observed in other outpatient populations such as other
popular categories of ambulatory surgery, including orthopedic surgery and eye surgery.
Summary
OSA is a public health crisis and an acknowledged epidemic. The burgeoning obesity
epidemic with the accompanying demand for cost-effective, efficient, and safe ambulatory
surgeries demand that health care professionals and anesthetists take responsibility for the safety
of patients beyond the procedure room and PACU.
Chapter 2 includes a review of the current literature related to obstructive sleep apnea in
general and in the ambulatory patient population in particular. Chapter 3 includes the
methodological procedures used to answer the research hypotheses. Chapter 4 consist of data
analysis derived from the pulse oximeter, cardiac monitor, and actigraph watch. Chapter 5
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provides a summary of findings, conclusions based on the findings, and end with
recommendations for implementation of safety initiatives and suggestions for further research.
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Chapter 2: Review of the Literature

Not much is known about what happens to ambulatory surgery patients on discharge.
There may be significant changes in the cardiopulmonary status of ASC patients that are
unknown and go undetected or untreated. The establishment of an “Obstructive Sleep Apnea
Death and Near Miss Registry” by the Society of Anesthesia and Sleep Medicine and the
Anesthesia Closed Claims Project is a step towards addressing these concerns (Biddle et al.,
2016). The objectives of the “Obstructive Sleep Apnea Death and Near Miss Registry” are to
help determine the level of monitoring at the time of death or near-miss and describe why the
adverse event happened to provide understanding of how best to study the phenomena (Biddle et
al., 2016). What occurs during the first 24 to 48 hours subsequent to same-day ASC surgery?
This literature review aims to show the inherent gaps as well as identify what may be known
about ambulatory surgery patients with OSA after they are released to their homes. The goal is to
show the need for a study intended to answer questions aimed at improving patient safety and
minimizing risks and adverse outcomes in the postoperative period.
In this chapter sleep apnea is defined before introducing the magnitude of the patient
safety problem of OSA in the general population and the impact this phenomenon has on
cardiopulmonary postoperative risks in the general surgical population. The chapter focuses on
these same risks as it affects the ambulatory surgery patient population. The chapter ends with a
summary.
15

Obstructive Sleep Apnea and the Surgical Patient
ASCs offer patients the convenience of having surgeries and procedures performed safely
outside a hospital setting. Endoscopic procedures are the largest driver of ASC growth
accounting for 32% of Medicare payments (Koenig, Doherty, Dreyfus, & Xanthopaulos, 2009).
In spite of the increase in number of ambulatory cases, adverse events are less than 1% and
major morbidity occurs with a frequency of approximately 0.1% (Kent et al., 2014).
Notwithstanding, as more Americans living with OSA receive ambulatory surgery, the likelihood
of increased postoperative morbidity and mortality is real.
OSA is one of several comorbidities that affect and is more prevalent in the surgery
population, which is more than the general population and puts patients at increased risk for
cardiopulmonary, neurocognitive, psychiatric, and gastrointestinal disorders, postoperative
complications, morbidity, and mortality (Ambrosii, Sandru, & Belii, 2016; Chiang et al., 2017;
Nagappa et al., 2017). The outpatient surgery population is particularly vulnerable, because
patients arrive with undiagnosed OSA and go home unmonitored after the immediate
postoperative/recovery period. In fact, a recent retrospective study showed that outpatients who
were determined to have OSA during their preoperative visit had more respiratory complications
than patients with known OSA (Fernandez-Bustamante et al., 2017). Fernandez-Bustamante et
al. (2017) did not address cardiovascular complications in their study. An estimated 26% (25
million) of Americans between the ages of 30 and 70 have sleep apnea (Peppard et al., 2013).
The incidence of undiagnosed OSA in patients undergoing endoscopy procedures is 40 to 43%
(Boese et al., 2014).
Patients with hypertension have a higher rate of screening positively for OSA (70%) than
those without hypertension (20%; Ge et al.,2013). Severe untreated OSA has been associated
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with increased all-cause and cardiovascular mortality (Fu et al., 2017; Wang et al., 2013). OSA
continues to be a common medical condition (Peppard et al., 2013) and is an important risk
factor for SCD (Gami et al., 2013). Nocturnal hypoxemia is an important pathophysiological
feature of OSA and strongly predicted SCD independently of well-established risk factors (Gami
et al., 2013). In a meta-analysis, Iftikhar, Valentine, and Bittencourt (2014) found a favorable
reduction of blood pressure with implementation of CPAP treatment in patients with recalcitrant
hypertension and sleep apnea. In another published study, Cintra, Leite, and Storti (2014) found
that nocturnal cardiac arrhythmias occurred in 92% of patients with severe sleep apnea compared
to 53% of people without sleep apnea. The prevalence of circadian rhythm disturbance also
increased with the severity of sleep apnea (Cintra et al., 2014).
The obesity epidemic and its associated co-morbidities, of which OSA is one, is likely to
result in an increased number of patients who arrive in outpatient centers for screening and
diagnostic endoscopies. Screening referrals will increase even more, particularly since OSA
patients are known to be at increased risk for cancers, including colorectal cancers (Fang, Miao,
Chen, Sithole, & Chung, 2015; Lee et al., 2017). So far, adverse events are rare (Rutter et al.,
2012; Stock et al., 2013), but as patients with multiple co-morbidities and more procedures
continue to be performed at ambulatory centers, this may change.
Sleep Apnea: Definition and Identification
OSA is the most common sleep disorder (Garcha et al., 2013). OSA is characterized by
frequent partial or complete collapse of the upper airway during sleep. This leads to decreased
blood oxygen levels (desaturation), increased respiratory effort, arousal, and sleep disruption.
Patients will typically present with witnessed apneic periods, loud snoring, and excessive
daytime somnolence. Hyper-somnolence resulting from fragmented sleep can increase
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probability of motor vehicle and other accidents, as well as decreased quality of life (Garcha et
al., 2013).
The Apnea-Hypopnea Index (AHI) is the measure used to delineate the severity of OSA.
Sleep apnea is rated as mild, moderate, or severe (Joshi et al. 2012). Mild is an AHI of -5 to 15
events per hour of sleep; moderate is -15 to 30 events per hour; severe is more than 30 events per
hour of sleep (Joshi et al., 2012). Polysomnography is still considered the reference standard for
diagnosing OSA. It is both time-consuming and expensive and must be performed in a sleep
laboratory. In the pre-operative setting, the Society for Ambulatory Anesthesia Consensus
recommended that the STOP-Bang Questionnaire be used as a screening tool to detect OSA
based on its high sensitivity and construct validity. (Joshi et al., 2012).
OSA is prevalent, though exact numbers are unknown, and is estimated to affect 10% to
17% of the U.S. population and as many as 49% in those of advanced ages (Peppard et al.,
2013). That estimate is based on greater than or equal to 15 events/hour AHI. At greater than or
equal to 5 events/hour AHI the overall population prevalence ranged from 9% to 38%. Among
the elderly, prevalence was as high as 90% for men and 78% for women. Exact prevalence is
undetermined partly because of variable criteria used to define disease, such as the number of
apneic episodes per hour, or whether there are accompanying specific signs or symptoms
(Senaratha et al., 2016; Young, Peppard, & Gottlieb, 2002).
Sleep Apnea and Cardiopulmonary Risk in the Surgical Population
OSA is associated with adverse physiological consequences, including cardiovascular
disease, hypertension, cognitive impairment, and metabolic abnormalities, such as type 2
diabetes; OSA is also associated with increased risk for postoperative cardiac and pulmonary
complications (Garvey, Pengo, Drakatos, & Kent, 2015). Several comorbidities that are
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frequently present in OSA patients reportedly result in higher mortality risks (Chiang et al.,
2017). Chiang et al. (2017) identified ten comorbidities that negatively impacted mortality of
OSA patients. The top two were hypertension and chronic obstructive pulmonary disease,
reflective of the negative impact OSA can have on cardiac and pulmonary physiology.
Nagappa et al. (2017a) completed the first meta-regression analysis comparing the
incidence of postoperative complications among surgical patients at high risk for OSA (HROSA) versus those at low risk for OSA. From their systematic review they found a prevalence of
33.3% HR-OSA in the surgical population. After non-cardiac surgical procedures, adverse
cardiopulmonary events were two to three times higher in OSA versus non-OSA patients, and in
patients with HR-OSA cardiopulmonary risk was as much as four times higher. There was also
an accompanying two-day increase in length of hospital stay. The authors felt that their analysis
supports the use of the STOP-Bang questionnaire as a perioperative risk stratification tool to
identify HR-OSA patients.
The strong association between arterial hypertension and OSA has been extensively
described, studied, and established (Mohsenin, 2014; Parati, Ochoa, Bilo, & Al, 2014).
Hypertension is common among OSA patients (35 to 80% affected) and appears to be directly
affected by OSA severity. Conversely, among hypertensive patients the percentages affected by
OSA range from approximately 40 to 50% (Parati et al., 2013). Moderate to severe OSA (AHI
15 to greater than 30 events per hour) is associated with a greater overall risk for cardiovascular
diseases. These cardiovascular diseases include hypertension, coronary artery disease, stroke,
congestive heart failure, and atrial fibrillation (Wang et al., 2013).
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Sleep Apnea and Cardiopulmonary Risk in the Outpatient Surgery Population
OSA is particularly prevalent in the outpatient surgery population with as many as one
fourth of patients undergoing elective surgery affected (Wolfe, Pomerantz, Miller, WeissColeman, & Solomonides, 2016). GI endoscopies are known to be the most frequently preformed
outpatient procedure, and patients who need gastrointestinal endoscopies also commonly have
OSA (Chien et al., 2015).
While it is known that OSA negatively impacts postoperative outcomes, there are very
few published studies that bear this out. Memtsoudis and Stundner (2014) analyzed data on over
500,000 hip and knee arthroplasty patients from over 400 institutions. These authors found that
OSA was associated with a 47% increased risk of postoperative major morbidity and increased
utilization of resources and length of stay (LOS). More recently, Ambrosii, Sandru, and Belii
(2016) conducted a prospective descriptive study in Romania that enrolled 400 patients and
reported that patients with OSA had 87.3% of postoperative complications and adverse events
compared to 12.6% for those without OSA. Additionally, a retrospective cohort analysis of 418
patients who had undergone outpatient colonoscopy was done to assess the association of BMI
and cardiopulmonary adverse events for ambulatory colonoscopy (Patel, Romain, Sanchez,
Fisher, & Schulteis, 2017). This study was important because it showed OSA to be an
independent risk factor for CAEs, independent of BMI and type or degree of sedation.
Obstructive Sleep Apnea and Patient Safety
Reason (2000) studied error management in clinical settings. The SCM was developed
from Reason’s studies and that holds that most errors or accidents are caused not so much by
unavoidable human error, but rather by an organization’s inadequate layers of error protection
that allow errors to pass through unchecked on their way to causing harm. These layers of
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protection are like slices of Swiss cheese with gaps that may allow errors to pass through
unchecked on their way to causing harm.
The holes in the SCM represent deficiencies in organizational defenses. Unlike holes in
real Swiss cheese, these holes are dynamic. They open, close, and change location over time.
Holes in these layers of protection happen for two reasons: active failures and latent conditions.
Latent conditions may allow holes to align and permit a trajectory of accident opportunity
bringing hazard or harm to the patient or system. The trajectory path ultimately shows that errors
result from holes in multiple layers of safeguards.
As many as 25% of patients undergoing surgery have OSA, but few hospitals or ASCs
have policies that address the risks of this condition during the perioperative period, and fewer
follow recommended consensus statements (Joshi et al., 2012). How patients with OSA are
identified, determined suitable for ambulatory surgery, and discharged after ambulatory surgery
represents a trajectory of problems inherent within the system that bring harm to patients. Not
considering the needs of patients with OSA in ASC settings and the possible associated cardiac
sequelae represents a latent risk factor that was mitigated by information generated by this study.
The study is innovative not only because of the use of three wearable body sensors, one
of which utilizes Bluetooth technology and near real-time monitoring, but because to date, none
have reported the clinical and ECG risk factors of cardiac risks that occur in this group of
patients, particularly in the 24 hours immediately following discharge from ambulatory surgery
(Rotenberg, 2013). Amidst this dearth of scientific evidence, organizations concerned with
patient safety such as the American Society of Anesthesiologists, have recommended that
patients with OSA be observed for extended periods of time and routinely receive CPAP; Joshi
et al., (2012). Some institutions require that certain populations of patients with OSA who have
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received particular narcotics be held overnight and not undergo surgery in ASCs (Rotenberg,
2013). Health care providers are rightfully concerned about the increased risk of adverse events
for OSA patients. These measures may prove to be unnecessary and are inconsistently practiced
(Memtsoudis & Stundner, 2014). More studies are needed to better identify patients who are at
risk and apply evidence-based interventions that will significantly improve and impact outcomes
and influence appropriate protocols to properly and efficiently manage these patients.
Summary
Based on the review of the literature, there has not been a study that has quantified both
the cardiac and pulmonary risk factors that either ambulatory surgical patients or ambulatory
patients undergoing endoscopies may be susceptible to in the immediate postoperative period (24
hours post procedure). The study was, therefore, designed to examine the prevalence of patient
and procedural risk factors for adverse cardiopulmonary events in patients presenting for
outpatient endoscopy under deep Propofol sedation and to determine the relative risk of adverse
cardiopulmonary events occurring in the first 24 hours at home in patients with and without
OSA. The following chapter sets forth the methodology of the study.
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Chapter 3: Methodology

Research Design
The study utilized a prospective, descriptive cross-sectional design and incorporated a
pre-test/post-test data collection approach. There was no manipulation of the independent
variable, operationalized as the presence or absence of OSA. This was coded as ‘0’ indicating
absence of OSA and ‘1’ presence of OSA. Presence of OSA was assessed based upon a STOPBANG (Snoring, Tired, Observed, Pressure, Body Mass Index, Age >50, Neck Size,
Gender = male) score greater than 3. The STOP-BANG is widely recognized as a reliable and
valid inventory for OSA and is widely used in both clinical research and clinical practice
domains (Cowan et al., 2014). The study had components of both a descriptive and a nonrandomized pre- and post-test design.
This study is objective and quantitative because the data yielded quantifiable answers to
closed-ended research questions. The equipment used to gather the data provided numerical data
only. Regression analyses, t-test analyses, and ANOVAs were the primary statistical methods
used.
This is a descriptive study because it aims to discover what are the cardiopulmonary risks
of outpatients with and without sleep apnea. It is also cross-sectional because it examined the
relationship between OSA, ambulatory surgery, and cardiopulmonary risk factors as delineated
in Table 1 (page 9).
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Selection of Subjects
The target population for the study consisted of outpatients scheduled for endoscopy,
recruited through the selected facility. Approximately 25,000 patients receive endoscopies at the
facility on a yearly basis, so enrollment of patients in using the facility was more efficient than
most other centers. The researcher recruited a convenience sample of participants to address the
research questions related to the prevalence of clinical and ECG cardiac risk factors of cardiac
risk in post-endoscopy outpatients with and without OSA. A convenience sampling approach
was appropriate because the researcher maintains a relationship with the doctors and staff of the
facility, and the researcher recruited participants who were easily accessible via the facility
(Acharya, Prakash, Saxena, & Nigam, 2013). A convenience sampling approach is best suited for
the study because it would be difficult to include a randomized sample of participants from the
target population (Etikan, Musa, & Alkassim, 2016).
Eligible participants were at least 18 years of age or older and scheduled to receive
sedation for endoscopy at the certified and credentialed endoscopy center. Participants were able
to independently review and complete the informed consent to participate in the study. Eligible
participants were fluent in either English or Spanish.
The final target sample was comprised of 50 adults scheduled to receive sedation for
endoscopic procedures at the ASC site. The center provides screening, detection, and polyp
removal for approximately 80 patients on a daily basis. Consequently, there was an adequate
flow of subjects for study inclusion. Subjects were approached during pre-procedure office visits
with their gastroenterologist. During the patients’ visits to the office, the principal investigator
(PI) discussed the study protocol with the patient and determined if he or she would be interested
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in consenting to participation in the study. The PI informed patients of the purpose of the study
and of the follow-up requirement in case of a concerning adverse event.
Eligible subjects were recruited from the endoscopy schedule 30 days prior to the
procedure up to two days preceding the procedure. The pre-anesthesia assessment was
completed, updated, or revised on the day of the procedure, as is standard and mandated
anesthesia practice. The ASC serves a diverse population and ensured an ethnically and
culturally diverse patient pool for recruitment. Because Holter monitors and pulse oximeters
must be returned and disinfected prior to use on subsequent subjects, the return of equipment
limited the speed of recruitment. Given the anticipated three-day turnaround time for equipment,
subjects generally received monitors on Mondays and Thursdays. The budget for the project
included rental of 6 BodyGuardian cardiac monitors, 10 pulse oximeters, and rental of 10
MicroMotionlogger Actigraph watches. Figure 1 illustrates the schedule of activities for the
study.
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Figure 1. Study chronology
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Study participants were assigned to one of three groups based on their STOP-BANG
scores and presence or absence of previous diagnosis of sleep apnea as follows: probability of
moderate to severe OSA (previously undiagnosed and untreated or diagnosed with treatment) or
low-risk OSA (no OSA) groups based on their STOP-BANG scores. A STOP-BANG score
greater than or equal to 3 is considered moderate to high risk for OSA (Table 2).
Table 2: STOP-BANG Grouping
Group
1

Score
<3

2

≥3

3

≥3

Diagnosis
Low risk or no OSA
Moderate to severe OSA
(previously undiagnosed and
untreated)
Moderate to severe OSA
(diagnosed with treatment)

Recruitment continued until 51subjects proceeded through enrollment and data
collection. One subject was removed because of incomplete data for a final count of 50 subjects.
Enrollment took place over a 4-month period. Power analyses were conducted for the regression
analysis using the number of times that an individual’s SpO2 level dropped below 90 (red) and
the duration of time that an individual spent with an SpO2 level below 90 (blue) on the STOPBANG measure. There are 11 dependent variables; of these 11 variables, two variables have
prototypical large and small expected effect sizes. The other 9 dependent variables fell
somewhere between these two extremes. The power of the STOP-BANG procedure to predict
number of significant SpO2 events is much larger than the power of the STOP-Bang procedure
to predict the duration of time spent in an event. Specifically, approximately 50 patients are
required to achieve 80% power to detect significant increases in the number of events associated
with higher STOP-Bang measures, while approximately 150 patients are required to achieve
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80% power to detect significant increases in the duration of such events. The strength of the
associations was based upon preliminary analyses from another project (Biddle et al., 2016). As
the current power analyses are a priori, it is possible that the associations observed are slightly
larger or smaller. To account for this, the shaded areas of Figure 2 show the power for a 20%
larger or smaller effect size.

Figure 2. Power analysis for detection of number of events.

Instrumentation
The STOP-BANG Questionnaire, a validated and reliable predictor of obstructive events
was used to classify subjects according to OSA risk (Cote et al., 2010; Cowan et al., 2014). For
surgical patients, the STOP-BANG Questionnaire is recommended for OSA screening because
of its ease of use and high degree of sensitivity. It is not feasible to have all patients undergo a
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sleep study preoperatively. Screening questionnaires can successfully identify at-risk patients
and allow the anesthesia provider to establish an early plan of care targeted at minimizing
intraoperative/postoperative complications.
The Respironics Nonin WristOx 3150 from Nonin Medical, Inc. Plymouth, MN is an
U.S. Food and Drug Administration-approved pulse oximeter, designed to be worn comfortably
on the patient’s wrist. It is well suited for in-home use and measures heart rate as well as arterial
oxygen saturation (SpO2). The device is activated when the soft probe is capped over a fingertip.
Sensitivity and negative likelihood ratio are reported at 100% and 0%, and specificity is of
100%. NONIN(R) Wrist Ox(R) 3100, 2005; Society of Anesthesia and Sleep Medicine. The
accuracy of the device is reported to be 70% to 100% SpO2 within +/- 2% SD and +3% for pulse
rate, with a bias of +0.03 and precision of +/- 2.08 SD. The accompanying software (nVision)
was used for analysis of the retrieved data.
The 9 high-risk ECG parameters can be seen in Table 1 (page 9). This table was created
based on a review of the literature to determine the appropriate ECG parameters used to assess
cardiac risk (Carey & Thevenin, 2009). These ECG parameters were derived from parameters
obtained using both a 12-lead ECG monitor before the procedure and the BodyGuardian cardiac
monitor for continued monitoring after the procedure. The BodyGuardian by Preventice
(Minneapolis, MN) is an FDA cleared device that is worn on the chest with the aid of bandage
patch. This cardiac monitor uses Bluetooth technology to deliver biometric data (i.e., ECG, heart
rate, activity level, and body position) securely to a smartphone which delivers the information to
the cloud in real time using the Sprint network while meeting Health Insurance Portability and
Accountability Act standards.
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The Micro-Motionlogger is an Actigraph watch validated against polysomnography
approved by the FDA for clinical research and use (Rupp & Balkin, 2011). The device has a triaxial digital micro-electromechanical system-based accelerometer that senses and measures
gravitational changes. Utilization of tri-axial dimensions result in increased reliability and less
variability between devices. The device is water-resistant, so it can be worn continuously for all
types of activities. The accompanying Action4 software sports up to 28 parameters from the
micro-motionlogger watch. This data provided information on sleep and non-parametric
circadian rhythm parameters.
Field Procedures
Participants were required to sign an IRB-approved informed consent form prior to
participation in the study. Documentation of the consent process was required including
documentation that follow-up requirements were reviewed with each patient. Within the 30 days
prior to the procedure, the investigator provided participants with written materials outlining the
study’s purpose, expected participation, duration, foreseeable risks, discomforts or
inconvenience, benefits of the research to society and the participant, and contact information for
the person to contact regarding questions or in the event of a research-related injury or
emergency. Pictures and written instructions for application and care of the monitors were also
provided to participants.
The investigator ensured that participants had sufficient time to review the material and
ask questions before completing the informed consent. Participants were informed that their
participation was voluntary and that refusal to participate would not result in any negative
consequences or loss of benefits to which they are entitled. The informed consent also included a
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statement regarding the participants’ right to confidentiality and right to withdraw from the study
at any time without any consequences.
Data Collection and Recording
Subjects were initially recruited during the office visit with the GI physician, Advanced
Registered Nurse Practitioner, or Physician Assistant. They were screened for inclusion pending
their expressed interest in participating in the study. Once the schedule was confirmed, which
generally occurred three days prior to the procedure, subjects who met inclusion criteria were
asked to return to the office to sign informed consent for the study. Following the consent
process, participants picked up the MotionWatch-8, pulse oximetry, completed the pre-operative
anesthesia assessment including the STOP-BANG, and had a baseline 12-lead ECG recording
then or on the day of the procedure. The subjects also had the option of having the information
packet (including the informed consent) sent electronically to allow enough time for review of
the documents and to ask questions. The pre-anesthesia assessment on pick up day included the
STOP-BANG Questionnaire for all the research participants. Enrolled participants were prepped
for the procedure per the facility standard. On day 1, participants began wearing the Actigraphy
watch which was to be worn continuously for a 3-day period. The Pulse Oximeter was worn
during hours of sleep on the first night of the study as well as the 24-hour period after receiving
anesthesia for the endoscopy (night three).
Subjects were re-assessed by the anesthesia team on the day of the procedure. The
cardiac monitor was worn during the 24-hour period immediately after discharge from the
recovery room on day three. On the fourth day all three monitors were either returned to the GI
doctor’s office or pick up was arranged. Data was retrieved from the returned monitors once they
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were returned. Monitors were cleaned, and batteries replaced if necessary. Monitors were then
ready for assignment to subsequent participants.
The subjects were continuously monitored by a CRNA while receiving Propofol sedation
during the endoscopy and up until transfer to the PACU. The patients were fitted with the cardiac
monitor by a research team member when fully awake and deemed fit for discharge. The PI was
available at all times for any concerns or questions participants had. All participants received a
$25 gift card when the monitors were returned.
Data Processing and Analysis
Preliminary Data Management. IBM SPSS version 24 was used for data management
and analysis. The dataset was screened for outliers prior to data analysis. Standardized values
were calculated for each continuous variable. Standardized values represent each data point’s
distance from the sample mean (Tabachnick & Fidell, 2013). Standardized values greater than
3.29 units from the sample mean were considered evidence of an outlying value (Stevens, 2009).
Outliers, defined as greater than three standard deviations from the mean, were removed from the
dataset so the data would not be skewed.
Research Questions and Hypotheses. RQ1: What is the prevalence of known ECG
characteristics for cardiac events among pre-endoscopic patients with high and normal STOPbang scores on resting 12-lead ECGs clinical (pulse oximetry and actigraph derived sleep quality
scores) and ECG characteristics of cardiopulmonary risk in post-endoscopy outpatients with
undiagnosed or untreated OSA, post-endoscopy outpatients receiving treatment for OSA, and
post-endoscopy patients without OSA?
RQ2: Among post-endoscopic patients receiving propofol, using a rhythm event recorder
(BodyGuardian Heart) are there statistically significant differences in the frequency of oxygen
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desaturation events and tachy-brady-arrhythmias over 24 hours between outpatients with
undiagnosed or untreated OSA, and post-endoscopy patients with and without a medical
diagnosis of OSA?
RQ3: Among pre-endoscopic patients receiving propofol, using a resting 12-lead ECG,
are there statistically significant differences in the duration of resting heart rate, QRS duration,
QTC duration and ST segment deviation between patients with low and high STOP BANG?
RQ4: Does sleep quality influence pulse oximetry readings? The variables included in the
study for Research Question 1 are clinical (pulse oximetry and Actigraph derived sleep quality
scores) and ECG risk factors of cardiac risk (Table 1). For Research Question 2, the dependent
variables are ECG and pulse oximetry. These dependent variables were compared among three
groups of participants: post-endoscopy outpatients with undiagnosed or untreated OSA, postendoscopy outpatients receiving treatment for OSA, and post-endoscopy patients without OSA.
The predictor variables for Research Question 3 are the comorbidities participants experience:
diabetes, hypertension, obesity, OSA. The criterion variable is the number of adverse events
participants experienced during the study. For Research Questions 4, the variables of interest are
sleep quality, number of adverse events, and pulse oximetry readings.
Statistical Analyses
Descriptive Statistics. The researcher conducted descriptive statistics to address
Research Question 1. Descriptive statistics to represent the prevalence of clinical (pulse oximetry
and actigraph derived sleep quality scores), ECG risk factors and participant group: postendoscopy outpatients with undiagnosed or untreated OSA, post-endoscopy outpatients receiving
treatment for OSA, and post-endoscopy patients without OSA. Frequencies and percentages
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were calculated for any categorical variables in the dataset (Howell, 2013). Means and standard
deviations were calculated for any continuous variables in the dataset (Howell).
Analysis of Variance (ANOVA). The researcher conducted ANOVAs for Research
Question 2 and 3. ANOVAs are the appropriate analysis to conduct when the researcher intends
to assess mean differences between more than two groups (Field, 2013). The independent
variables for the analyses are patient group (operationalized as post-endoscopy outpatients with
undiagnosed or untreated OSA, post-endoscopy outpatients receiving treatment for OSA, and
post-endoscopy patients without OSA) and sleep quality, operationalized as sleep efficiency
measure from the Actigraph watch. The ANOVA allowed the researcher to assess statistically
significant differences in the dependent variable by the groups corresponding to each
independent variable (Pallant, 2013). A Tukey post hoc analysis was conducted to determine
where the statistically significant differences lie between groups (Pagano, 2010). An a priori
alpha level has been set at .05.
Multiple Linear Regressions. For Research Question 4 the researcher conducted a
multiple linear regression. Multiple linear regressions are appropriate for analysis of the
predictive relationship between a set of predictor variables and a criterion variable (Pagano,
2010). The researcher conducted multiple linear regressions to assess the predictive relationships
between comorbidities and the number of adverse events participants experience. The researcher
reported the F statistic and p value to indicate the statistical significance of the overall regression
model (Pallant, 2013). The R2 was reported to represent the amount of variation in the criterion
variable that can be attributed to the predictor variables (Field, 2013). An a priori alpha level has
been set at .05.
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Limitations
The results must be viewed with respect to the study’s limitations. The study was
conducted with patients receiving Propofol sedation for outpatient endoscopies. While
surveillance occurred both 24 hours before and after the procedure, it is ideal to monitor for an
additional 24hr period of time. These results cannot be translated to the general surgical
population or all outpatients.
Summary
The methodology as set forth in this quantitative longitudinal pre/post study, utilizing
four instruments (STOP-bang questionnaire, Pulse oximeter, Actigraph watch, cardiac monitor);
aims to describe, identify and quantify cardiopulmonary risk factors for outpatients in the 24
hours post endoscopy. The following chapter summarizes and present the collected data,
statistical treatment and analysis of the data.
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Chapter 4: Findings

The purpose of this study was to assess the prevalence of patient risk factors for
cardiopulmonary adverse events in a diverse range of patients presenting for outpatient
endoscopy under deep propofol sedation, and to determine the relative risk of adverse
cardiopulmonary events occurring in the first 24-hours post-procedure following deep propofol
sedation for endoscopy in patients with or without OSA
Over 4 months, 51 outpatients were recruited and consented to participate in this research
study. One was removed because of incomplete data set for a final count of 50 subjects. Most
outpatients in the sample were women (n = 35, 70%) and most had colonoscopy procedures
(n = 44, 86%). Thirty eight percent of the participants had a STOP-BANG score greater than
three and were therefore categorized as likely to have sleep apnea. Nine participants (18%) had a
medical diagnosis of OSA, seven (14%) of whom had a medical diagnosis of OSA and used
home CPAP. Fifteen participants were hypertensive (30%; Table 3).
Table 3: Sample Characteristics, N = 50
Characteristic
Female
Colonoscopy
STOP-Bang Score ≥3
Medical Diagnosis of Sleep Apnea
Home CPAP
Hypertensive (120/80 mmHg)

N
35
44
19
9
7
15
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%
70
86.3
38
18
14
30

Table 4 presents frequencies and percentages for the number of participants presenting
with sleep apnea according to their STOP-Bang scores. Scores lower than 3 on the STOP-Bang
questionnaire are considered evidence that the participant is unlikely to have sleep apnea, while
scores greater than or equal to 3 are likely indicative of sleep apnea. Participants with low risk of
sleep apnea represented most of the sample (n = 31, 62%).

Table 4: Frequencies and Percentages for Participants without Sleep Apnea (STOP-Bang ,3)
and with Sleep Apnea (STOP-Bang ≥ 3), N = 50
N
31
19

No
Yes

%
62
38

Table 5 presents frequencies and percentages for the number of participants who reported
a medical diagnosis of sleep apnea. The majority of participants indicated that they did not have
a medical diagnosis (n = 41, 82%).

Table 5: Frequencies and Percentages for Participants Reporting a Medical Diagnosis of Sleep
Apnea, N = 50
N
41
9

No
Yes

%
82
18

Table 6 presents frequencies and percentages for participants exhibiting a fragmented
QRS (fQRS) morphology and abnormality (notching and fragmentation) of QRS. A fQRS
morphology was indicated by less than 2 R’ or notching in the nadir of the S wave with QRS less
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than 120 or 2 R’ or notching in the nadir with wide QRS (Virk Hassan, Farooq, Ghani, & Arora,
2016). The majority of the sample data indicated no fQRS morphology (n = 44, 88%). Most
participants did not exhibit QRS abnormality (n = 32, 64%).

Table 6 Frequencies and Percentages for Participants Exhibiting fQRS Morphology and
Exhibiting QRS Abnormality, N = 50
fQRS Abnormality
No
Yes
QRS Abnormality
No
Yes

N

%

44
6

88
12

32
18

64
36

Table 7 presents frequencies and percentages for presence of Premature Ventricular
Contractions (PVCs) in participants. Almost all participants (n = 48, 96%) did not exhibit PVC.
Table 7: Frequencies and Percentages for Presence of PVC in Participants, N = 50
N
48
2

No
Yes

%
96
4

Table 8 presents frequencies and percentages for the presence of a depression or
elevation of 1.00 mm in any of the leads. Most participants did not exhibit a depression or
elevation of 1.00 mm in any of the leads (n = 40, 80%).
Table 8: Frequencies and Percentages for Participants Exhibiting Depression or Elevation of
1.00 mm in Leads
N
40
10

No
Yes

38

%
80
20

Table 9 presents descriptive statistics for participants’ age, STOP-Bang Score, and heart
rate measures. The average of participants was 54.48 (SD = 12.34). STOP-Bang scores ranged
from zero to six with an average of 2.24 (SD = 1.42). The average heart rate for participants was
72.16 (SD = 11.32) and the average QRS duration was 86.66 (SD = 17.22). Finally, the mean
QTc interval was 431.10 (SD = 30.40) and the mean ST segment in V1 was 139.40 (SD = 41.82).

Table 9: Descriptive Statistics for Participants’ Age STOP-Bang Score, and Heart Rate
Measures
Age
STOP-BANG Score
Heart Rate- mean R-R intervals for all QRS
complexes during the duration of the recordings
QRS duration- mean QRS duration on standard
12 lead ECG
QTc interval per Bazett- Mean QRS onset to T
offset interval of all leads
ST segment in V4

Minimum
30
0
50

Maximum
M
83
54.48
6
2.24
102
72.16

SD
12.34
1.42
11.32
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145

86.66

17.22

363

537

431.10 30.40

80

320

139.40 41.82

Pre-Procedure 12-Lead ECG Analysis
RQ1: Among pre-endoscopic patients receiving propofol, using a resting 12-lead ECG,
what were the baseline ECG risk factors for cardiovascular events present in the recording? All
subjects were in the cardiac rhythm of normal sinus. The most prevalent ECG risk factor of
cardiac events were notched QRS complexes which is a marker for ventricular scarring (Virk
Hassan, Farooq, Ghani, & Arora, 2016). Nearly a quarter (n = 10, 20%) had ST segment
deviation on the pre-procedure 12-lead ECG indicating possible myocardial ischemic or reduced
coronary perfusion (Carey, 2016). Table 10 presents frequencies and percentages for aberrant
ECG characteristics.
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Table 10: Aberrant ECG Characteristics
N
2
4
18
6
10

Premature Ventricular Contraction (PVC)
Left Ventricular Hypertrophy (LVH)
Notched QRS complex
Fragmented QRS (fQRS)
ST segment event

%
4
8
36
12
20

Table 11 shows that the resting heart rates were normal and neither bradycardic or
tachycardic. On average the other measures of duration, QRSd and QTc were normal as well as
the magnitude of the ST segment.
Table 11: Normal ECG Characteristics
M
72
87
431
139

Resting Heart Rate (beats per minute)
QRS Duration (milliseconds)
QTc duration (milliseconds)
ST segment deviation (millimeters)

SD
11
17
30
42

Post-Procedure Event Recorder Analysis
Regarding the rhythm event recorder worn for 24 hours, the mean heart rate was 78.14
(SD = 11.05). Mean tachycardic, or fast, heart rate maximum was 114, with a mean of 91.35
(SD = 37.19). The mean bradycardic, or low, heart rate ranged from 50 to 78, with a mean of
38.33 (SD = 27.62). Table 12 presents 24-hour heart rate information for participants.
Table 12: 24-hour Mean Heart Rate Data for Participants
Overall heart rate
Tachycardic heart rate
Bradycardic heart rate

Minimum
58
99
50

Maximum
103
114
78
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Mean
78.14
91.35
38.33

SD
11.05
37.19
27.62

RQ2: Among post-endoscopic patients receiving propofol, using an event recorder, are
there statistically significant differences in the frequency of tachy- and brady- arrhythmias over
24 hours between outpatients with no diagnosis of OSA and a STOP-BANG score less than 3,
outpatients with untreated OSA, and outpatients with a medical diagnosis?
A one-way ANOVA was conducted between three groups of participants: participants
with no diagnosis of OSA and a STOP-BANG score less than 3 (Group 1); participants with
untreated OSA (Group 2); and participants with a medical diagnosis (Group 3). The frequency of
tachy-arrhythmias and brady-arrhythmias among those three groups was compared. Tables 13
and 14 present descriptive statistics for the three groups of participants.
Table 13: Descriptive Statistics for Participants with No OSA, Untreated OSA, and a Medical
Diagnosis of OSA, Tachycardia
Group
1
2
Mean Tachy HR
3
Total
1
% of time Tachy over 2
24 hours
3
Total
1
Length of longest
2
uninterrupted Tachy
3
episode in Minutes
Total

N
28
13
9
50
28
13
9
50
28
13
9
50

M
99.50
79.31
81.89
91.08
11.25
11.15
6.78
10.42
27.399
30.10
22.47
27.21

SD
28.32
46.06
46.53
37.52
13.30
18.54
7.00
13.88
43.49
60.82
29.86
45.83
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Std. 95% C.I. for M
Error Lower Upper
5.35 88.52 110.48
12.78 51.47 107.14
15.51 46.12 117.66
5.31 80.42 101.74
2.51
6.09 16.41
5.14
-.05 22.36
2.33
1.40 12.16
1.96
6.48 14.36
8.22 10.53 44.25
16.87 -6.65 66.85
9.95 -0.48 45.43
6.48 14.19 40.23

Min
0
0
0
0
0
0
0
0
.00
.00
.00
.00

Max
114
111
110
114
50
50
20
50
209.59
194.43
84.48
209.59

Table 14: Descriptive Statistics for Participants with No OSA, Untreated OSA, and a Medical
Diagnosis of OSA, Bradycardia
95% C.I. for M
Std.
Group N
M
SD
Error Lower Upper Min
Max
1
28
37.61 28.87 5.46
26.41 48.80
0 78
2
13
34.08 28.15 7.81
17.07 51.09
0 58
Mean Brady HR
3
9
44.67 25.42 8.47
25.13 64.21
0 61
Total 50
37.96 27.77 3.93
30.07 45.85
0 78
1
28
5.97
9.16
1.73
2.41
9.52
0 35
% of time Brady over 2
13
14.62 21.26 5.90
1.77
27.46
0 56
24 hours
3
9
10.00 15.92 5.31
-2.24 22.24
0 48
Total 50
8.94
14.56 2.06
4.80
13.08
0 56
1
28
11.97 19.75 3.73
4.31
19.63
.00 71.20
Length of longest
2
13
14.55 19.72 5.47
2.63
26.46
.00 58.17
uninterrupted brady
3
9
13.57 19.65 6.55
-1.54 28.67
.00 51.09
event in Minutes
Total 50
12.93 19.35 2.74
7.43
18.43
.00 71.20
The results of the ANOVAs comparing the frequencies of tachy- and brady-arrhythmias
between the three groups were not statistically significant (Table 15). These findings indicate
that the frequencies of tachy-and brady-arrhythmias were similar across the three groups of
participants. Because there were no statistically significant findings no post hoc testing was
conducted.
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Table 15: Results of the ANOVAs Comparing Frequencies of Tachy- and Brady-arrhythmias
Between the Three Groups of Participants

Between
Within
Total
Between
% of time Tachy over
Within
24 hours
Total
Length of longest
Between
uninterrupted Tachy Within
episode in Minutes
Total
Between
Mean Brady HR
Within
Total
Between
% of time Brady over
Within
24 hours
Total
Length of longest
Between
uninterrupted brady
Within
event in Minutes
Total
Mean Tachy HR

Sum of
Squares
4547.02
64432.66
68979.68
145.68
9292.50
9438.18
311.26
102587.60
102898.86
604.32
37177.60
37781.92
676.30
9717.25
10393.56
63.35
18284.16
18347.51

df
2
47
49
2
47
49
2
47
49
2
47
49
2
47
49
2
47
49

Mean
Square
2273.51
1370.91

F

p

1.66

.201

72.84
197.71

0.37

.694

155.63
2182.72

0.07

.931

302.16
791.01

0.38

.685

338.15
206.75

1.64

.206

31.68
389.03

0.08

.922

RQ3: Among pre-endoscopic patients receiving propofol, using a resting 12-lead ECG,
are there statistically significant differences in the duration of resting heart rate, QRS duration,
QTC duration and ST segment deviation between patients with low and high STOP BANG?
Table 16 presents mean differences and p-values for comparison of ECG measures for
high and low STOP-Bang groups. The t-test showed that across all ECG measures there were no
statistically significant differences in mean ECG measure values across the two groups. All the
p-values exceeded .05, therefore the researcher failed to reject the null hypothesis.
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Table 16: Comparison of Means between Patients with High and Low STOP-BANG (Low < 3,
High ≥ 3)
ECG Measure
Resting HR (beats per minute)
QRS duration (milliseconds)
QTc (milliseconds)
ST segment (millimeters)

Mean Difference
2.7
-4.7
0.925
14.3

p-value
0.415
0.353
0.918
0.244

RQ4: Does sleep quality influence pulse oximetry readings? Table 17 presents the results
of the regression analyses conducted to assess the relationship between sleep quality and pulse
oximetry readings. Statistical significance was found across several of the variables; however,
the predictors accounted for minimal variation in the criterion variables.

Table 17: Results of the Regressions for Duration and SEFF
Variables
Duration
D0.sleeptime ~ duration.2
Dn1.spo2_90 ~ duration.3
AVEn1_spo290 ~ duration.3
AVEd0_spo290 ~ duration.3
AVEd1_spo290 ~ duration.3
SEFF
D0.sleeptime ~ seff.2
D1.sleeptime ~ seff.2
seff.3 ~ ASA Class
dn2.spo2_90 ~ seff.3
AVEn2_spo290 ~ seff.3
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df1

df2

F

p

R2

1
1
1
1
1

32
31
31
32
12

4.92
4.90
6.78
4.96
5.42

0.03
0.03
0.01
0.03
0.04

0.11
0.11
0.15
0.11
0.25

1
1
1
1
1

32
12
48
25
25

10.02
8.52
5.18
4.33
5.39

0.00
0.01
0.03
0.05
0.03

0.21
0.37
0.08
0.11
0.14

Chapter 5: Discussion

OSA is a disorder characterized by the intermittent cessation of breathing for at least 10
seconds while the affected person sleeps (Garcha et al., 2013). OSA is a prevalent public health
concern affecting approximately 22 million Americans (Parati et al., 2014). The present study is
important because it is estimated that 80% of the population with OSA is undiagnosed, and many
patients with OSA remain undiagnosed at the time of surgery (Parati et al., 2014). Singh et al.
(2013) reported that surgeons and anesthetists failed to identify up to 58% of surgical patients
who had OSA as confirmed by polysomnography. OSA increases the mortality and morbidity of
patients requiring general anesthesia, sedation, or intravenous opioids, increasing their risk for
perioperative complications as much as four times that of patients without OSA (Kaw et al.,
2012).
The purpose of this quantitative cross sectional pre/post study was to evaluate the
prevalence of cardiopulmonary risk factors among post-endoscopic patients with diagnosed and
undiagnosed sleep apnea in the 24-hour period after surgery. This chapter includes a discussion
of the results obtained from the cardiac, pulse oximetry, and Actigraphy devices worn by
participants. The chapter also includes a discussion of the implications of the results for
perioperative teams in positively impacting outpatient safety during the perioperative period. The
chapter concludes with a discussion of implications for practice, recommendations for future
research, and a summary.
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The research questions were: RQ1: What is the prevalence of known ECG characteristics
for cardiac events among pre-endoscopic patients with high and normal STOP-bang scores on
resting 12-lead ECGs, clinical (pulse oximetry and Actigraphy derived sleep quality scores) and
ECG characteristics of cardiopulmonary risk in post-endoscopy outpatients with undiagnosed or
untreated OSA, post-endoscopy outpatients receiving treatment for OSA, and post-endoscopy
patients without OSA?
Notched QRS complexes are a marker for ventricular scarring (Virk Hassan, Farooq,
Ghani, & Arora, 2016) and were the most prevalent ECG risk factor of cardiac events.
Additionally, 20% (n=10) had ST segment deviation on the pre-procedure 12-lead ECG
indicating possible myocardial ischemic or reduced coronary perfusion (Carey, 2016)Table 9.
Pulse oximetry and actigraph derived sleep quality scores revealed no difference based on OSA.
RQ2: Among post-endoscopic patients receiving propofol, using a rhythm event recorder
(BodyGuardian Heart) are there statistically significant differences in the frequency of oxygen
desaturation events and tachy-brady-arrhythmias over 24 hours between outpatients with
undiagnosed or untreated OSA, and post-endoscopy patients with and without a medical
diagnosis of OSA?
ANOVA results comparing the frequencies of tachy- and brady-arrhythmias between the
three groups were not statistically significant (Table 11). Lack of significance means that
frequencies of tachy-and brady-arrhythmias were similar across the three groups of participants.
The ANOVA for oxygen desaturation events and sleep quality indices similarly reflected no
differences across the three groups.
RQ3: Among pre-endoscopic patients receiving propofol, using a resting 12-lead ECG,
are there statistically significant differences in the duration of resting heart rate, QRS duration,
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QTC duration and ST segment deviation between patients with low and high STOP BANG? The
t-test for sleep quality indices reflected no differences between low and high STOP-bang groups.
The presence or absence of OSA had no effect across groups on desaturation events or frequency
of tachy-brady arrhythmias. Sleep quality also had no measurable influence on adverse events
and was similar across all three groups, although participants diagnosed with OSA slept
significantly longer than those in the untreated or no OSA group.
RQ4: Does sleep quality influence pulse oximetry readings? The regressions for sleep
quality indices similarly reflected no differences between the three groups.
Conclusions
The study described the prevalence of known ECG characteristics for cardiac events
among pre-endoscopic patients with high and normal STOP-bang scores on resting 12-lead
ECGs, clinical (pulse oximetry and actigraph derived sleep quality scores) and ECG
characteristics of cardiopulmonary risk in post-endoscopy outpatients with undiagnosed or
untreated OSA, post-endoscopy outpatients receiving treatment for OSA, and post-endoscopy
patients without OSA. The statistical level of significance expected for adverse events (oxygen
desaturation and tachy-brady-arrhythmias) occurring in either of the groups in the 24 hours after
the procedure was not achieved. Notwithstanding, there was an interesting incidental finding.
Approximately one quarter up to a third of the participants had ECG markers on their baseline
12-lead that indicated decreased coronary perfusion, myocardial ischemia, or possible ventricular
scarring. This is an unexpectedly interesting finding and latent hazard, given that no participants
reported any previous significant cardiac event, nor did having these markers result in acute
adverse events for the participants. In this sample, 20% of subjects (who would have otherwise
been unidentified) without a medical diagnosis of OSA were identified as having undiagnosed
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OSA based on STOP-bang scores. Pre-operative under diagnosis of OSA by anesthetists and
surgeons represents one-way patients are exposed to avoidable risks.
While the results yielded no significant findings, several points are apparent. The
importance of the preoperative anesthesia evaluation as a first line of defense against latent
opportunities for hazard to become harm must be reiterated. In the Singh et al. (2013) study,
almost 40% of patients with OSA confirmed by PSG only had one or two principal symptoms of
OSA. At minimum, a proven screening tool like STOP-bang should be included as a requisite
part of a thorough preoperative assessment.
In addition to the STOP-bang survey, the opportunity exists to use inexpensive readily
available tools such as ECG to minimize risk and optimize results for outpatients during the
vulnerable perioperative period. One-third of the subjects in this study had ECG high-risk
markers that indicated possible myocardial scarring or compromised coronary perfusion. Biteker,
Duman, and Tekkesin (2011) studied the predictive value of the preoperative ECG for
perioperative cardiovascular outcomes in patients undergoing noncardiac, nonvascular surgery.
Based on their findings, Biteker et al. (2011) recommended that prolonged QTc be viewed as an
independent marker for preoperative cardiovascular outcome after noncardiac, nonvascular
surgery.
While there was no significant instances of tachycardia or bradycardia post-procedure,
the findings of these ECG markers highlight the role an individualized and complete
preoperative assessment, that includes an ECG, can make towards thoughtful perioperative
management and positive postoperative outcomes. The 12-lead ECG is inexpensive, convenient,
and accessible to most outpatients. Although a pre-op ECG is not a current requirement for
asymptomatic patients undergoing low-cardiac-risk surgery, individual patient factors such as an
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above average BMI, having at least one risk factor for coronary artery disease, and consideration
of OSA risk (assessed by STOP-BANG) should allow the ECG to be considered as part of an
anesthesia pre-operative assessment.
There was an instance where a participant with the medical diagnosis of OSA had a
STOP Bang score of less than 3. The patient attributed consistent use of CPAP in improving
blood glucose levels to where the patient was no longer diabetic or obese.
Limitations
This is the first study to monitor patients in their homes with cardiac, actigraphy, and
pulse oximetry. It was a challenge ensuring compliance with all three devices. The patients were
required to wear three separate monitors. A heart monitor on the chest with an accompanying
phone, an actigraphy watch on one wrist, and during sleep a pulse oximeter on the other wrist.
One patient woke to find that all three monitors had been removed during sleep. Another patient
went swimming in the watch and decided not to share that it quit working until the day of the
procedure. Such issues with devices may have affected study results and partially explain
findings of non-significance. The Bodyguardian with Bluetooth real-life monitoring was easiest
to track, as the PI could check or allow notification in real time if the device was not being worn.
The sample size of 50 was the minimum needed to achieve 80% power to detect
significant increases in the number of events associated with higher STOP-Bang measures. A
larger, stratified sample of 150 or more may have improved statistical power. Examination of a
power analysis graph indicated that increasing the number of participants did not greatly increase
the statistical power of the analysis. The increase in statistical power from increasing the sample
size did not justify the resource constraint (e.g., securing additional monitoring devices for
additional participants) that would result from recruiting more participants. The researcher opted
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to use a sample of 50 participants. The participants were only receiving propofol for endoscopy
procedures. While this may be a strength in the uniformity of the drug received, the results may
not generalize well to all outpatients who may receive general anesthesia or other classes of
drugs (i.e., opioids, benzodiazepines, etc.) for other types of outpatient procedures. This study
only included patients receiving sedation for endoscopy procedures that did not require postoperative pain management and cannot be generalized to patients receiving general anesthesia
who may require post-operative pain management and control.
Implications for Practice
Propofol anesthesia has taken the dread out of screening colonoscopies, resulting in an
easier sale on the part of gastroenterologists encouraging patients to get screening colonoscopies.
Anesthetists are often not included in the pre-operative evaluation of patients. This task is
usually the job of the primary attending physician or specialist to whom the patient has been
referred. Typically, anesthetists review the medical information on the day of the procedure,
immediately preceding the patient’s entrance to the procedure room. On occasion, potential
patient safety aberrancies are caught at the last moment and procedures are cancelled resulting in
loss of time and revenue. The pressure is sometimes placed on the anesthetist to “just do the
case” since, as evidenced by this study, patients often proceed through anesthetics without
incident. The onus is on the anesthetist to place patient safety first. During the procedure, it may
be noted that the patient may have OSA symptoms (i.e., an obstructed airway necessitating
additional airway maneuvers) while under anesthesia. This is an opportunity for anesthetists to
address the public health dilemma of undiagnosed OSA and help direct patients to appropriate
resources for OSA screening. Pre-op clinics are not a reimbursable expense for insurance

50

purposes, but the payoff in perioperative patient safety and potential savings on public health
costs would be well worth it.
Outpatients go home unmonitored. This may not be considered serious after procedures
that do not require pain medication during recovery, but for outpatient procedures such as
bariatric and orthopedic surgery that may require pain control at home this becomes life
threatening. Pain control at home combined with the current opioid crisis lends itself to yet
another latent and potentially deadly hazard. The importance of recognizing OSA, signs of
opioid abuse, and the utilization of anesthetic modalities that minimize and or eliminate narcotic
use and overuse should be encouraged in a multidisciplinary approach. Patients identified as
having OSA by STOP-bang should be referred for a sleep study to ensure pulmonary
optimization before and after surgery. Noncompliant OSA patients who do not use CPAP should
be counseled on the importance of using their equipment. Case in point was one patient in the
study who converted to atrial fibrillation in the early morning after the procedure. The patient
had fallen asleep without wearing CPAP. After a call from the company, the patient replaced the
CPAP and spontaneously reverted to sinus rhythm.
Similarly, patients with high-risk ECG markers signaling coronary perfusion issues or
arrhythmia triggers may have their treatment customized to better ensure their safety during and
after the procedure. Telemonitoring at home also could be made available when pertinent. The
obligation should be on the perioperative team to ensure that during perioperative screening
patients have the relevant equipment and that safety measures are anticipated and implemented.
There is an opportunity for anesthetists to be important not only at the head of the OR
table as clinicians, but as leaders in patient safety initiatives affecting public health, such as the
opioid crisis and OSA, and even smoking cessation. Anesthetists should embrace the role of
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patient safety advocate beyond the OR. Patients should be educated on the life-threatening
physiological and quality of life consequences of not using CPAP when indicated.
Recommendations for Future Research
This the first and only in-home study of utilizing three devices before and after surgical
procedures. A pre- and post-test design was chosen for this longitudinal study to improve on a
previous post-test study by Biddle et al. (2016) involving pulse oximetry monitoring of
outpatients after orthopedic surgery. A convenience sample was used for this study for ease of
recruitment and particularly because RQ1 was designed to identify the prevalence of known
high-risk markers ECG characteristics in the outpatient endoscopy population. A Quota sampling
technique would be helpful in future studies to hone in on the undiagnosed (high STOP-BANG
score) OSA population. Further research might also include outpatient surgery populations that
require general anesthesia and post-operative pain control.
Future studies might use an integrated Bluetooth monitor with integrated features to help
facilitate patient compliance. Spence, Han, Morrison, and Couture (2018) completed an in home
prospective observational study of patients undergoing total joint arthroplasty. The researchers
started out with one sleep monitor and switched to another sleep monitor mid study mainly
because of patient complaints of how uncomfortable the first device was to wear. The WatchPAT200 (Itamar Medical Ltd, Caesarea, Israel) the researchers eventually used to complete their
study, is an FDA approved device that incorporates both pulse oximeter and Actigraph
capabilities and could have reduced the device number to two versus three thereby helping
enhance patient compliance.
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Conclusion
No differences were found between patients with and without OSA 24-hours postprocedure following deep propofol sedation for endoscopy. The findings suggest that Propofol
sedation may be safe for patients with OSA. Additionally, preoperative screening or postoperative follow-up may not be necessary for Propofol sedation in patients with OSA, which can
help to reduce healthcare costs. There were exactly enough patients to satisfy the power analysis
with a sample size of 50, which was the minimum number needed to achieve 80% power to
detect significant increases in the number of events associated with higher STOP-Bang
measures. Findings should be interpreted with this limitation in mind, and replication of the
study with a larger and stratified sample size is recommended.

53

References
Acharya, A., Prakash, A., Saxena, P., & Nigam, A. (2013). Sampling: Why and how of it? Indian
Journal of Medical Specialities, 4(2), 330-333.
Ambrosii, T., Sandru, S., & Belii, A. (2016, October 23). The prevalence of perioperative
complications in patients with and without obstructive sleep apnea: a prospective cohort
study. Rom J Anaesth Intensive Care, 23(2), 103-110.
http://dx.doi.org/https://dx.doi.org/10.21454%2Frjaic.7518%2F232
American Hospital Association. (2014). Trends affecting hospitals and health systems
[Chartbook]. Retrieved from
http://www.aha.org/research/reports/tw/chartbook/index.shtml
Benumof, J. L. (2016). Mismanagement of obstructive sleep apnea may result in finding these
patients dead in bed. Can J Anaesth, 63(1), 3-7. doi:10.1007/s12630-015-0513-x
Biddle, C., Elam, C., Lahaye, L., Kerr, G., Chubb, L., & Verhulst, B. (2016). Predictors of athome arterial oxygen desaturation events in ambulatory surgical patients. Journal of
Patient Safety, 1-6. Retrieved from http://www.journalpatientsafety.com
Biteker, T., Duman, B., & Tekkesin, S. (2011, November). Predictive value of Preoperative
Electrocardiography for Perioperative Cardiovascular outcomes in patients undergoing
noncardiac, nonvascular surgery. Clinical Cardiology, 8(35).
Boese, M. L., Ransom, R. K., Roadfuss, R. J., Todd, L. A., & McGuire, J. M. (2014, February).
Utility of the Berlin questionnaire to screen for obstructive sleep apnea among patients
receiving intravenous sedation for colonoscopy. AANA Journal, 82(1), 38-45. Retrieved
from http://www.aana.com/newsandjournal/Documents/berlin-quest-screen-obstrucsleep-apnea-0214-p38-45.pdf
54

Carey, M. (2016, September). Acute Coronary Syndrome and ST Segment Monitoring. Criterion
Care Nurses Clinic North America, 347-355.
Carey, M. G., & Thevenin, B. J. (2009). High-resolution 12-lead electrocardiograms of on-duty
professional firefighters: a pilot feasibility study. Journal of Cardiovascular Nursing,
24(4), 261-267. http://dx.doi.org/doi: 10.1097/JCN.0b013e3181a4b250
Chiang, C., Chen, Y., Wang, K., Yi-Fong Su, V., Wu, L., Perng, D., . . . Chou, K. (2017).
Comorbiditites and risk of mortality in patients with sleep apnea. Annals of Medicine,
49(5), 377-383. http://dx.doi.org/doi: 10.1080/07853890.2017.1282167
Chien, S., O'Connell-Goff, S., Tang, S., Chien, K., & Ho, S. (2015, December). Prevalence of
obstructive sleep apnea in an ambulatory colonoscopy clinic. Sleep Medicine, 16(S1),
212. http://dx.doi.org/http://dx.doi.org/10.1016/j.sleep.2015.02.1444
Cintra, F. D., Leite, R. P., & Storti, L. J. (2014, September 23). Sleep apnea and nocturnal
cardiac arrhythmia: a populational study. Arq Bras Cardiol. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/25252161
Fang, H., Miao, N., Chen, C., Sithole, T., & Chung, M. (2015, September 15). Risk of cancer in
patients with insomnia, parasomnia, and obstructive sleep apnea: a nationwide nested
case-control study. Journal of Cancer, 6(11), 1140-1147.
http://dx.doi.org/https://dx.doi.org/10.7150%2Fjca.12490
Fernandez-Bustamante, A., Bartels, K., Clavijo, C., Scott, B., Kacmar, R., Bullard, K., . . .
Jameson, L. (2017, August). Intraoperative-ventilation: incidence and risk factors for
receiving large tidal-volumes during general anesthesia. Anesthesia & Analgesia, 125(2),
593-602. http://dx.doi.org/ DOI: 10.1213/ANE.0000000000002241
55

Field, S. (2013). Looping state of mind. New York, NY: Cengage Learning.
Fu, Y., Xia, Y., Yi, H., Xu, H., Guan, J., & Yin, S. (2017, March). Meta-analysis of all-cause and
cardiovascular mortality in obstructive sleep apnea with or without continuous positive
airway pressure treatment. Sleep Breath, 21(1), 181-189. http://dx.doi.org/
doi: 10.1007/s11325-016-1393-1.
Gami, A., Olson, E., Shen, W., Wright, R., Ballman, K., Hodge, D., . . . Somers, V. (2013).
Obstructive sleep apnea and the risk of sudden cardiac death. Journal of the American
College of Cardiology, 62(7), 610-616.
http://dx.doi.org/(http://dx.doi.org/10.1016/j.jacc.2013.04.080)
Garcha, P., Aboussouan, L., & Minai, O. (2013). Sleep-Disordered Breathing. Retrieved from
Cleveland Clinic Center for Continuing Education website:
http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/pulmonary/slee
p-disordered-breathing/
Garvey, J. F., Pengo, M. F., Drakatos, P., & Kent, B. D. (2015, ). Epidemiological aspects of
obstructive sleep apnea. Journal of Thoracic Disease, 7.
http://dx.doi.org/10.3978/j.issn.2072-1439.2015.04.52
Ge, X., Han, F., Huang, Y., Zhang, Y., Yang, T., Bai, C., & Guo, X. (2013, July 25). Is
obstructive sleep apnea associated with cardiovascular and all-cause mortality? PLoS
One, 8(1). http://dx.doi.org/https://doi.org/10.1371/journal.pone.0069432
Hall, M., Schwartzman, A., Zhang, J., & Liu, X. (2017). Ambulatory surgery data from hospitals
and ambulatory surgery centers: United States, 2010 (DHHS Publication No.2017-1250).
Washington, DC: Government Printing Office.

56

Howell, D. (2013). Fundamental Statistics for the behavioral sciences. New York, NY: Cengage
Learning.
Iftikhar, I. H., Valentine, C. W., & Bittencourt, L. R. (2014, September 19). Effects of
continuous positive airway pressure on blood pressure in patients with resistant
hypertension and obstructive sleep apnea: a meta-analysis. Journal of Hypertens.
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25243523
Joseph, D. A., Meester, R. G., Zauber, A. G., Manninen, D. L., Winges, L., Dong, F. B., . . . van
Ballegooijen, M. (2016, ). Colorectal cancer screening: estimated future colonoscopy
need and current volume and capacity. Cancer, 122(16), 2479-86.
http://dx.doi.org/10.1002/cncr.30070
Joshi, G. P., Ankchetty, S. P., Gan, T. J., & Chung, F. (2012, November). Society for
Ambulatory Anesthesia consensus statement on preoperative selection of adult patients
with obstructive sleep apnea scheduled for ambulatory surgery. Anesth Analg, 115(5),
1060-8. http://dx.doi.org/doi: 10.1213/ANE.0b013e318269cfd7
Kaw, R., Pasupuleti, V., Walker, E., Ramaswamy, A., & Foldvary-Schafer, N. (2012).
Postoperative complications in patients with obstructive sleep apnea. Chest, 141, 436-41.
Kent, C., Metzner, J., & Bollag, L. (2014). An analysis of risk factors and adverse events in
ambulatory surgery. Ambulatory Anesthesia, 1, 3-10.
http://dx.doi.org/http://dx.doi.org/10.2147/AA.S53280
Lee, S., Kim, B., Kim, J., Lee, K., Koo, D., Nam, H., . . . Koh, S. (2017, March). Obstructive
sleep apnea is associated with an increased risk of colorectal neoplasia. Gastrointestinal
Endoscopy, 85(3), 568-573. http://dx.doi.org/doi.org/10.1016/j.gie.2016.07.06

57

Liu, Y., Wheaton, A., Chapman, D., Cunningham, T., Lu, H., & Croft, J. (2014). Prevalence of
healthy sleep duration among adults-United States, 2014 (MMWR 2016;65).
Washington, DC: Government Printing Office.
Mador, M. J. (2013). Postoperative complications in obstructive sleep apnea. Sleep Breath,
17(2), 727-34. http://dx.doi.org/10.1007/s11325-012-0750-y.
Memtsoudis, S., & Stundner, O. (2014, February). The impact of sleep apnea on postoperative
utilization of resources and adverse outcomes. Anesthesia and Analgesia, 118(2),
407-411.
Mohsenin, V. (2014, October). Obstructive sleep apnea and hypertension: a critical review.
Current Hypertens Research, 16(10). http://dx.doi.org/https://doi.org/10.1007/s11906014-0482-4
Mutter, T. C., Chateau, D., & Moffatt, M. (2014, October). A matched cohort study of
postoperative outcomes in obstructive sleep apnea: could preoperative diagnosis and
treatment prevent complications? Anesthesiology, 121(4), 707-718.
Nagappa, M., Ho, G., Patra, J., Singh, M., Kaw, R., Cheng, D., & Chung, F. (2017, October 17).
Postoperative outcomes in obstructive sleep apnea patients undergoing cardiac surgery: a
systematic review and meta-analysis of comparative studies. Anesth Analg.
http://dx.doi.org/doi: 10.1213/ANE.0000000000002558
Nagappa, M., Patra, J., Wong, J., Subramini, Y., Singh, M., Ho, G., . . . Chung, F. (2017,
October). Association of STOP-Bang questionnaire as a screening tool for sleep apnea
and postoperative complications: a systematic review and Bayesian meta-analysis of
prospective and retrospective cohort studies. Anesthesia & Analgesia, 125(4), 1301-1308.
http://dx.doi.org/doi: 10.1213/ANE.0000000000002344
58

National Center on Sleep Disorders Research (NCSDR). (2011). National Institutes of Health
Sleep Disorders Research Plan (NIH Publication No. 11-7820). Washington, DC:
Government Printing Office.
Pagano, A. M. (2006). Journeys of women without custody: From ambivalence to a renewed
sense of self. Bloomington, IN: AuthorHouse.
Pallant, J. F. (2013). SPSS survival manual: A step by step guide to data analysis using IBM
SPSS. Maidenhead, England: McGraw Hill.
Parati, G., Lombardi, C., Hedner, J., Bonsignore, M., Grote, L., Tkacova, R., . . . McNicholas,
W. (2013). Recommendations for the management of patients with obstructive sleep
apnoea and hypertension. Eur Respir Journal, 41(3), 523-538. http://dx.doi.org/DOI:
10.1183/09031936.00226711
Parati, G., Ochoa, J., Bilo, G., & al, E. (2014). Obstructive sleep apnea syndrome as a cause of
resistant hypertension. Hypertens Research, 37(1), 601-613. http://dx.doi.org/ doi:
10.1038/hr.2014.80.
Patel, V., Romain, P., Sanchez, J., Fisher, D., & Schulteis, R. (2017, October). Obstructive sleep
apnea increases the risk of cardiopulmonary adverse events associated with ambulatory
colonoscopy independent of body mass index. Dig Dis Sci, 62(10), 2834-2839.
http://dx.doi.org/10.1007/s10620-017-4731-7
Peppard, P. E., Young, T., & Barnet, J. H. (2013, May). Increased prevalence of sleep-disordered
breathing in adults. American Journal Epidemiol, 177(9), 1006-1014.
Reason, J. (2000). Human error: models and management. BioMed Journal, 320, 768-770.

59

Rotenberg, B. (2013, December 3). Early perioperative outcomes after surgery for sleep apnea: a
current review of the literature. Current Anesthesiology Reports.
http://dx.doi.org/10.1007/s40140-013-0041-6
Rupp, T. L., & Balkin, T. J. (2011). Comparison of motion logger watch and actwatch actigraphs
to polysomnography for sleep/wake estimation in healthy young adults. Behavioral
Research Methods, 43(4), 1152-1160. http://dx.doi.org/doi: 10.3758/s13428-011-0098-4.
Rutter, C., Johnson, E., Miglioretti, D., Mandelson, M., Inadomi, J., & Buist, D. (2012, Jul 27).
Adverse events after screening and follow-up colonoscopy. Cancer Causes Control,
23(2), 289-296. http://dx.doi.org/https://dx.doi.org/10.1007%2Fs10552-011-9878-5
Senaratha, C. V., Perret, J. L., Lodge, C. J., Lowe, A. L., Campbell, B. E., Matheson, M. C., . . .
Dharmage, S. C. (2016, ). Prevalence of obstructive sleep apnea in the general
population: A systematic review. Sleep Medicine Reviews.
http://dx.doi.org/http://dx.doi.org/10.1016/j.smrv.2016.07.002
Singh, M., Liao, P., & Kobah, S. (2013). Proportion of surgical patients with undiagnosed
obstructive sleep aponia. Br J Anapest, 110, 629-636.
Spence, D., Han, T., Morrison, T., & Couture, D. (2018). High rate of undiagnosed obstructive
sleep apnea in patients undergoing total joint arthroplasty. AANA Journal, 86(4), 282-288
Stevens, M. (2009). A primer of ecology with R. New York, NY: Springer.
Stock, C., Ihle, P., Sieg, A., Schubert, I., Hoffmeister, M., & Brenner, H. (2013, March). Adverse
events requiring hospitalization within 30 days after outpatient screening and
nonscreening colonoscopies. Gastrointestinal Endsocopy, 77(3), 419-429.
http://dx.doi.org/http://dx.doi.org/10.1016/j.gie.2012.10.028

60

Tabachnick, B., & Fidell, L. (2013). Using multivariate statistics (6th ed ed.). Boston, MA:
Allyn and Bacon.
(Virk Hassan, Farooq, Ghani, & Arora, 2016) July 1, QRS fragmentation: it's role in sherlocking
the arrhymogenic heart, Journal of Community Hospital Internal Medicine Perspectives,
Wang, X., Ouyang, Y., Wang, Z., Zhao, G., Liu, L., & Bi, Y. (2016). Obstructive sleep apnea
and risk of cardiovascular disease and all-cause mortality: a meta-analysis of prospective
cohort studies. International Journal of Cardiol, 169(3), 207-14. http://dx.doi.org/
10.1016/j.ijcard.2013.08.088
Wolfe, R., Pomerantz, J., Miller, D., Weiss-Coleman, R., & Solomonides, T. (2016). Obstructive
sleep apnea: preoperative screening and postoperative care. Journal of the American
Board of Family Medicine, 29(6), 263-275.
http://dx.doi.org/10.3122/jabfm.2016.02.150085
Young, T., Peppard, P. E., & Gottlieb, D. J. (2002). Epidemiology of obstructive sleep apnea: a
population health perspective. American Journal Respiratory Critical Care, 9(165),
1217-1239.

61

Appendix A

62

Depiction of pulse oximeter
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Depiction of micromotionlogger watch
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Appendix B

Stop-Bang Questionaire

Depiction of Reason’s Swiss Cheese Model
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Appendix C
Spanish Informed Consent
Información relacionada con temas de la investigación y formulario de
consentimiento
Título: Evaluación de de la base de referencia y los factores de riesgo después de
la descarga en sujetos con y sin apnea del sueño que se someten a endoscopia con
sedación profunda.
NÚMERO DEL PROTOCOLO DE VCU IRB: HM20008241
Patrocinador: AANA Foundation (Fundación de AANA)
Si existe información en este formulario de consentimiento que no está claro, puede pedirle
al personal del estudio que le explique cualquier información que no entienda
completamente. Puede discutir esto con su familia o amigos hoy, pero necesitamos que
firme su formulario de consentimiento hoy para matricularse.
PROPÓSITO DEL ESTUDIO
El propósito de este estudio es comparar los cambios en el estado de los sujetos con y
sin apnea del sueño, antes y después de la sedación.
DESCRIPCIÓN DEL ESTUDIO Y SU PARTICIPACIÓN
Si decide participar en este estudio de investigación, se le pedirá que firme este formulario
de consentimiento después de haber respondido a todas sus preguntas y entender lo que le
sucederá.
Se someterá a un examen físico y un cuestionario antes de la cirugía que todos los pacientes
deben someterse antes de la cirugía. Le preguntaremos acerca de sus antecedentes
médicos y quirúrgicos, medicamentos, alergias, revise su expediente médico completo. Esta
información rutinaria también se utilizará en el estudio. Además de esta información
rutinaria, también se le harán preguntas para completar el cuestionario de STOP-BANG
(para determinar la probabilidad de tener la apnea del sueño) y un electrocardiograma de
12 plomos (ECG) también se realizará en la mañana del procedimiento. Ambos se suman a
su preparación preoperatoria habitual y son necesarios para las actividades de
investigación.
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Si acepta este estudio, le pediremos que use un monitor cardíaco que es un tipo de
electrocardiograma ambulatorio (ECG). Este dispositivo registrará la actividad eléctrica
de su corazón continuamente mientras se está moviendo durante sus actividades
habituales y durante el sueño. Se adjuntará con pequeñas almohadillas o parches
(electrodos) pegados en el pecho (ver demostración adjunta) después de su
procedimiento. También llevarás un reloj de movimiento (como Fitbit) y un monitor de
oxígeno (mide el porcentaje de oxígeno en la sangre) antes y después del procedimiento.
El monitor de oxígeno sólo se llevará en la muñeca y el dedo (vea la demostración
adjunta) siempre que descansa o duerme.
En el segundo día, devolverá el monitor del corazón, el reloj de movimiento y el monitor
de oxígeno al equipo de investigación en el sobre de franqueo pagado que se
proporciona. Estará en un grupo de cerca de 100 otros pacientes de cirugía y su
información permanecerá confidencial. Usará el reloj del movimiento y el oxímetro del
pulso por 3 días y el monitor del corazón por 1 día. Su compromiso de tiempo total será
de 4 días.
RIESGOS Y MOLESTIAS
Hay un riesgo de malestar menor cuando se usan los monitores, especialmente el monitor
de oxígeno. Para asegurar la comodidad, ajuste la correa de velcro de modo que no esté
demasiado apretada.
Puede usarlo en cualquiera de las muñecas. También, utilice la punta de prueba plástica
suave del dedo en cualquier dedo que sienta es más cómodo. La cinta adhesiva que se usa
para fijar los electrodos del monitor cardíaco debe ser removida cuidadosamente para
evitar la irritación de la piel. Vamos a hacer preguntas para completar el cuestionario
STOP-Bang y hacer un ECG de 12 plomos. Ambas actividades relacionadas con la
investigación no supondrán ningún riesgo adicional para y pueden proporcionar
información adicional importante y útil a los médicos que proveen su cuidado.
Existe también un riesgo potencial de pérdida de confidencialidad. Este riesgo se
minimizará al almacenar su información de manera segura y de acuerdo con todas las
reglas de la HIPAA y la confidencialidad de la investigación.

USO Y DIVULGACIÓN DE INFORMACIÓN PROTEGIDA DE SALUD
Autoridad para Solicitar Información Protegida de Salud
Las siguientes personas y / o grupos pueden solicitar mi información protegida de
salud:
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•

Investigador Principal e Investigación

•

Personal del Patrocinio del Estudio

•

Colaboradores de Investigación

•

Juntas Institucionales de Evaluación

•

Juntas de supervisión de seguridad de
datos

•

Agencias de Gobierno / de Salud

•

Otros según lo requerido por la ley

Autoridad para Divulgar Información Protegida de Salud
El Baptist Health System (BHS) puede divulgar la información indicada en este
formulario de autorización de mi antecedente médico para proporcionar esta
información a:
•
•
•
•
•

Proveedores de atención médica de
BHS
Proveedores de atención médica de
VCUHS
Coordinadores de datos
Juntas de supervisión de seguridad
de datos
Otros según lo requerido por la ley

•

Investigador principal y personal de
investigación
Colaboradores de Investigación

•
•

Juntas Institucionales de Evaluación
Agencias de Gobierno / de Salud

•

Patrocinador del Estudio

•

Una vez que su información de salud ha sido divulgada a alguien fuera de este estudio, la
información ya no puede ser protegida bajo esta autorización.
Tipo de información que se puede divulgar
Los siguientes tipos de información se pueden ser utilizados para la realización de esta
investigación:
•

Antecedente de salud completo

•

•
•

Historia y examen físico
Informes de consulta

•
•

Resultados de las pruebas de
laboratorio
Informes de las radiografías
Información del abuso de drogas o
alcohol

Caducidad de esta autorización
•

Esta autorización expirará cuando se cierre el estudio de investigación o no sea
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necesario revisar, analizar y considerar los datos generados por el proyecto de
investigación, lo que sea posterior.
Derecho a revocar la autorización y la Re-divulgación
Puede cambiar de opinión y revocar (retirar) el derecho de usar su información protegida
de salud en cualquier momento. Aunque revoque esta Autorización, todavía los
investigadores pueden usar o divulgar su información de salud que ya han recopilado para
este estudio. Si revoca esta Autorización, ya no podrá participar en el estudio de
investigación. Para revocar esta Autorización, debe escribir al Investigador Principal.
BENEFICIOS PARA Y OTROS
No puede recibir ningún beneficio directo de este estudio. Su participación puede ayudar a
su equipo de atención médica para identificar a los pacientes en riesgo de eventos futuros
cardiopulmonares después de la cirugía.

COSTOS
No hay costos por su participación en este estudio, excepto por su tiempo para recuperar y
usar los monitores antes y después del procedimiento.
PAGO PARA LA PARTICIPACIÓN
Recibirá una tarjeta de regalo Visa de $25. Para recibir esta tarjeta de regalo, tiene que
llevar los monitores el día antes y después del período de 24 horas después del
procedimiento. Debe enviar por correo los monitores al equipo de investigación en el
sobre que se proporciona. Después de que el equipo de investigación reciba sus
monitores, le enviaremos la tarjeta de regalo a su dirección que nos proporcione.
ALTERNATIVOS
Tiene la opción de no participar en este estudio.
CONFIDENCIALIDAD
Su información potencialmente identificable consistirá en sus antecedentes médicos,
examen físico y medidas de monitoreo. Los datos se están recopilando sólo con fines de
investigación.
Sus datos serán identificados por un código numérico, no por nombres, y serán
archivados en un programa informático protegido por contraseña. Toda la información
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personal se guardará en archivos protegidos por contraseña y estos archivos se
eliminarán al final del estudio. El acceso a todos los datos estará limitado al personal del
estudio.
Lo que encontramos en este estudio puede ser presentado en reuniones o publicado en
artículos, pero su nombre no se usará en estas presentaciones o artículos.
PARTICIPACIÓN VOLUNTARIA Y RETIRO
No tiene que participar en este estudio. Si decide participar, puede detenerse en
cualquier momento sin ninguna penalización. También puede optar por no contestar
preguntas particulares que se hacen en el estudio.
Su participación en este estudio se puede ser detenida en cualquier momento por el
personal del estudio o el patrocinador sin su consentimiento. Las razones podrían
incluir:
•
•
•
•

el personal del estudio piensa que puede ser necesario para su salud o seguridad;
no cumplió con las instrucciones del estudio.
el patrocinador ha detenido el estudio;
o motivos administrativos exigen su retiro.

Si deja el estudio antes de la visita final programada, devuelva los 3 monitores en el sobre
proporcionado. No recibirá el pago por la participación si no completa completamente el
monitoreo durante las 24 horas completas después de la cirugía.

CUESTIONES
Si tiene alguna pregunta, queja o inquietud con respecto a su participación en esta
investigación, comuníquese con:
Mercedes Weir, CRNA, MSN: Investigadora asociada
Galloway Endoscopy Center
7500 SW 87th Ave
Miami, FL 33173
Móvil: (786) 999-9000
Correo electrónico: weirm@vcu.edu
Chuck Biddle, CRNA, PhD: Investigador Principal
Virginia Commonwealth University
School of Allied Health Professions
P.O Box 980226
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Richmond, VA 23298-0226
Teléfono: (804) 828-9808
Correo electrónico: nrsa@vcu.edu

La investigadora asociada anteriormente mencionada es la mejor persona para
ponerse en contacto con respecto a preguntas relacionadas con su participación
en este estudio.
Si tiene alguna pregunta en cuanto a sus derechos, no dude en ponerse en contacto con:
Oficina de la Investigación
Virginia Commonwealth University
800 East Leigh Street, Suite 3000
P.O. Box 980568
Richmond, VA 23298
Teléfono: (804) 827-2157
Póngase en contacto con este número para preguntas generales, preocupaciones o
quejas relacionadas con la investigación. También puede llamar a este número si no
puede comunicarse con el equipo de investigación o si desea hablar con otra persona.
También se puede encontrar información general en cuanto a la participación en los
estudios de investigación en http://www.research.vcu.edu/irb/volunteers.htm.

CONSENTIMIENTO
Se me ha dado la oportunidad de leer este formulario de consentimiento. Entiendo la
información relacionada con este estudio. Las preguntas que quería hacer con respecto al
estudio se han sido contestadas. Mi firma significa que estoy dispuesto a participar en este
estudio. Recibiré una copia del formulario de consentimiento una vez que haya aceptado
participar.

Nombre impreso del participante Firma del participante

Fecha

Nombre de la persona que realiza la discusión de consentimiento informado. (Impreso)
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Firma de la persona que realiza el consentimiento informado.
Discusión

Fecha

Investigador Principal Firma (Si es diferente del anterior)

Fecha
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Appendix D
Research Subject Information and Consent Form (English)
Title: Assessing Baseline and Post-Discharge Risk Factors in Subjects with and without Sleep
Apnea Undergoing Endoscopy with Deep Sedation.
VCU IRB PROTOCOL NUMBER: HM20008241
Sponsor: AANA Foundation

If any information contained in this consent form is not clear, please ask the study staff to
explain any information that you do not fully understand. You may discuss this with your
family or friends today, but we need your signed consent today to enroll.
PURPOSE OF THE STUDY
The purpose of this study seeks to compare changes in status of subjects with and without
sleep apnea, before and after sedation.
DESCRIPTION OF THE STUDY AND YOUR INVOLVEMENT
If you decide to be in this research study, you will be asked to sign this consent form after you
have had all your questions answered and understand what will happen to you.
You will undergo a pre-surgery physical and questionnaire that all patients have before
surgery. We will ask about your medical and surgical history, medicines, allergies, review your
full medical record. This routine information will also be used in the study. In addition to this
routine information, you will also be asked questions in order to complete the STOP-BANG
questionnaire (helps determine likelihood of you having sleep apnea) and a 12-lead
electrocardiogram (ECG) will also be done on the morning of the procedure. Both of these are
in addition to your usual pre-operative preparation and are a necessary part of the research
activities.

If you consent to this study, we will ask you to wear a Heart monitor which is a type of
ambulatory electrocardiogram (ECG). This device will record your heart’s electrical activity
continuously while you move around doing your usual activities and during sleep. It will be
attached with small pads or patches (electrodes) taped to your chest (see attached
demonstration) after your procedure. You will also wear a Motion watch (like a Fitbit) and an
oxygen monitor (measures the percentage of oxygen in your blood) before and after your
procedure. The oxygen monitor will only be worn on your wrist and finger (see attached
demonstration) whenever you rest or sleep.
On the second day, you will return the heart monitor, motion watch. and oxygen monitor to
the research team in the postage-paid envelope provided. You will be in a group of about 100
other surgery patients and your information will remain confidential. You will wear the motion
watch and pulse oximeter for 3 days and the Heart monitor for 1 day. Your total time
commitment will be 4 days.
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RISKS AND DISCOMFORTS
There is a risk of minor discomfort when wearing the monitors, particularly the oxygen monitor.
To ensure comfort, adjust the Velcro strap so that it is not too tight.
You may wear it on either wrist. Also, wear the soft plastic finger probe on whichever finger you
feel is more comfortable. The adhesive tape used to attach the electrodes of the heart monitor
must be removed carefully to avoid skin irritation. We will ask questions to complete the STOPBANG questionnaire and do a 12 lead ECG Both of these research related activities will pose no
additional risk to you and may provide additional important and useful information to clinicians
who provide your care.
There is also a potential risk for loss of confidentiality. This risk will be minimized by storing
your information as securely and in keeping with all HIPAA and research confidentiality rules.
USE AND DISCLOSURE OF PROTECTED HEALTH INFORMATION
Authority to Request Protected Health Information
The following people and/or groups may request my protected health information:

•
•
•
•

Principal Investigator and Research Staff
Research Collaborators
Data Safety Monitoring Boards
Others as Required by Law

•
•
•

Study Sponsor
Institutional Review Boards
Government/Health Agencies

Authority to Release Protected Health Information
The Baptist Health System (BHS) may release the information identified in this
authorization form from my medical records and provide this information to:

•
•
•
•
•

Health Care Providers at BHS
Health Care Providers at VCUHS
Data Coordinators
Data Safety Monitoring Boards
Others as Required by Law

•
•
•
•
•

Principal Investigator and Research Staff
Research Collaborators
Institutional Review Boards
Government/Health Agencies
Study Sponsor

Once your health information has been disclosed to anyone outside of this study, the
information may no longer be protected under this authorization.
Type of Information that may be Released
The following types of information may be used for the conduct of this research:

•
•
•

Complete health record
History and physical exam
Consultation reports

•
•
•

Expiration of This Authorization
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Laboratory test results
X-ray reports
Information about drug or alcohol abuse

•

This authorization will expire when the research study is closed, or there is no need to
review, analyze and consider the data generated by the research project, whichever is
later.

Right to Revoke Authorization and Re-disclosure
You may change your mind and revoke (take back) the right to use your protected health
information at any time. Even if you revoke this Authorization, the researchers may still use or
disclose health information they have already collected about you for this study. If you revoke
this Authorization you may no longer be allowed to participate in the research study. To revoke
this Authorization, you must write to the Principal Investigator.
BENEFITS TO YOU AND OTHERS
You may not receive any direct benefit in this study. Your participation might help your health
care team identify future patients at risk for cardiopulmonary events after surgery.
COSTS
There are no costs for your participation in this study except for your time to retrieve and wear
the monitors before and after your procedure.
PAYMENT FOR PARTICIPATION

You will receive a $25 Visa gift card. In order to receive this gift card, you need to wear the
monitors the day before and after the 24-hour period after your procedure. You must mail the
monitors to the research team in the provided envelope. After the research team receives your
monitors we will mail the gift card to your address you provide to us.
ALTERNATIVES
You have the option to not participate in this study.
CONFIDENTIALITY
Potentially identifiable information about you will consist of your medical history, physical, and
monitor measurements. Data is being collected only for research purposes.
Your data will be identified by a number code, not names, and stored in a password
protected computer program. All personal identifying information will be kept in passwordprotected files and these files will be deleted at the end of the study. Access to all data will
be limited to study personnel.

What we find from this study may be presented at meetings or published in papers, but your
name will not ever be used in these presentations or papers.
VOLUNTARY PARTICIPATION AND WITHDRAWAL

You do not have to participate in this study. If you choose to participate, you may stop at any
time without any penalty. You may also choose not to answer particular questions that are
asked in the study.
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Your participation in this study may be stopped at any time by the study staff or the
sponsor without your consent. The reasons might include:
•
•
•
•

the study staff thinks it necessary for your health or safety;
you have not followed study instructions;
the sponsor has stopped the study;
or administrative reasons require your withdrawal.

If you leave the study before the final regularly scheduled visit, return the 3 monitors in the
provided envelope. You will not receive payment for participation if you do not fully complete
monitoring for the full 24 hours after surgery.

QUESTIONS
If you have any questions, complaints, or concerns about your participation in this research,
contact:
Mercedes Weir, CRNA, MSN: Co-Investigator
Galloway Endoscopy Center
7500 SW 87th Ave
Miami, FL 33173
Cell: (786) 999-9000
Email: weirm@vcu.edu
Chuck Biddle, CRNA, PhD: Principal Investigator
Virginia Commonwealth University
School of Allied Health Professions
P.O Box 980226
Richmond, VA 23298-0226
Phone: (804) 828-9808
Email: nrsa@vcu.edu

The co-investigator named above is the best person to call for questions about your
participation in this study.
If you have any general questions about your rights as a participant in this or any other
research, you may contact:
Office of Research
Virginia Commonwealth University
800 East Leigh Street, Suite 3000
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P.O. Box 980568
Richmond, VA 23298
Telephone: (804) 827-2157
Contact this number for general questions, concerns or complaints about research. You may
also call this number if you cannot reach the research team or if you wish to talk with
someone else. General information about participation in research studies can also be found
at http://www.research.vcu.edu/irb/volunteers.htm.
CONSENT
I have been given the chance to read this consent form. I understand the information about this
study. Questions that I wanted to ask about the study have been answered. My signature says
that I am willing to participate in this study. I will receive a copy of the consent form once I have
agreed to participate.

Participant name printed

Participant signature

Date

Name of Person Conducting Informed Consent Discussion (Printed)

Signature of Person Conducting Informed Consent
Discussion

Date

Principal Investigator Signature (if different from above)

Date
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Vita
Mercedes Ermita Weir was born on September 7, 1967, in Buff Bay, Portland, Jamaica,
West Indies. She is a naturalized citizen of the United States of America. She graduated from
Kingsway High School in Kingston, Jamaica in 1983. She received her Diploma in Nursing from
Kingston School of Nursing in Kingston, Jamaica in 1988 and her Bachelor’s in Nursing from
Southern Adventist University, Chattanooga, Tennessee in 1994. After 10 years of Oncology and
Critical Care Clinical experience she attended the State University of New York at Buffalo
(SUNY Buffalo) and completed her Masters of Science in Nursing with a concentration in Nurse
Anesthesia. In 2013 she was accepted as a doctoral candidate at Virginia Commonwealth
University. She currently continues her clinical practice as Certified Registered Nurse
Anesthetist (CRNA) in various Locums assignments across the United States.
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